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GENERAL INTRODUCTION 
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ADENOSINE 
 
Adenosine is an ubiquitous purine nucleoside, playing a fundamental role in many biological 
processes such as energy generation and proteins metabolism, but in the last two decades it has 
become clear that adenosine is a mediator involved in the pathogenesis of many inflammatory 
disorders. Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar 
molecule (ribofuranose) via a β-N9-glycosidic bond (Figure 1). 
 
 
 
 
 
 
 
 
Figure 1: Adenosine structure 
 
Adenosine is present in every cell of the body and its cytoplasmic concentration is tightly 
regulated. The levels of adenosine are determined primarily from the dephosphorylation of 
its immediate precursor, adenosine monophosphate (AMP). Precursors of AMP include 
cyclic AMP (cAMP), adenosine diphosphate (ADP) and adenosine triphosphate (ATP). ATP 
is co-released with other neurotransmitters from presynaptic vesicles and is also produced by 
mast cells, basophiles and endothelial cells and as result of cellular damage. ADP is derived 
from activates platelets, while cyclic AMP serves as a second messenger in most cells. In 
normoxic condition the estimated ratio of ATP: AMP is approximately 50:1; when the total 
ATP levels decrease, for example in ischemic tissues where the oxygen supply is strongly 
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reduced, there are a large production and so increase in AMP and adenosine (Linden, 1994). 
It is so clear that the important role of adenosine is to protect the cell when a decrease of 
oxygen supply could compromise the physiological cellular function and survival. Adenosine 
nucleotide is degraded by a series of ectonucleotidases. One such enzyme, 5’-nucleotidase, 
catalyses the conversion of AMP to adenosine during increased cellular metabolism. 5’-
nucleotidase is found both extracellularly (attached to the plasma membrane by glycosyl-
phosphatidylinositol anchors) and in the cytosol. Regulation of the activity and/or expression 
of this enzyme is critical for regulation of the levels of adenosine.  
Adenosine is also produced from the hydrolysis of S-adenosylhomocysteine (SAH), by S-
adenosylhomocysteine hydrolase. This mechanism is responsible of a significant portion of 
the adenosine present under resting conditions. S-adenosylhomocysteine also serves as an 
intracellular binding protein for adenosine, thereby protecting the nucleoside from 
degradation. Adenosine is rapidly cleared from the extracellular space through a bi-
directional facilitates transporter that is sensible to the drug dipyridamole. So, the 
administration of dipyridamole increases interstitial adenosine levels, in accordance to the 
pharmacological actions of this drug, which include coronary vasodilatation, sedation and 
anticonvulsant action. Under normoxic conditions, adenosine is phosphorylated by adenosine 
kinase to AMP and subsequently to ATP to restore the nucleotide pool. However, under 
conditions of increased metabolic stress, the increased levels of adenosine easily saturate 
adenosine kinase and excess adenosine is metabolised to inosine and hypoxanthine by 
adenosine deaminase (Figure 2). 
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Figure 2: Metabolism of adenosine 
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Adenosine receptors  
A large number of hormones, neurotransmitters and neuromodulators that regulate the 
interactions between cells, exert their effects by interacting with specific G protein-coupled 
receptors (GPCRs). In 1978, Burnstock proposed the existence of almost two types of 
receptors for purines, called P1 and P2. This distinction was based on the order of potency of 
various nucleotides and nucleosides: P1 identifies the family of receptors more sensitive to 
adenosine, whereas P2 receptors are preferentially activated by ATP and ADP (Burnstock, 
1978). A further criterion of differentiation between P1 and P2 receptors is based on different 
sensitivity to antagonists with xanthine structure. In particular P1 receptors are inhibited 
competitively by drugs such as caffeine, xanthine, theophylline and theobromine, which are 
inactive on P2 receptors. This general division into P1 and P2 receptors has been the basis for 
the current classification and nomenclature of these receptors. Each of the two families 
includes several receptor subtypes identified by pharmacological profile, the mechanism for 
translating the signal and the molecular structure (Fredholm et al., 2001). P1 receptors are 
divided in 4 subtypes, localized at the cytoplasmic membrane (A1, A2A, A2B, A3) and have a 
variable distribution in different systems (central nervous system, cardiovascular, renal, 
respiratory, immune and gastrointestinal), where they modulate normal biological functions 
(Ralevic and Burnstock, 1998). Previously, adenosine receptors (ARs) have been classified 
according to their molecular structure, their pharmacological profile and their mechanism of 
signal transduction (Fredholm et al., 2001). Each subtype is coupled to a particular type of G 
protein, which may be stimulatory (Gs) or inhibitory (Gi). In some tissues, A1 and A3 
receptors are able to modulate the activity of phospholipase C (PLC) and, in the case of A1 
receptors, ion channels for Ca2+ or K+.Considering the overall protein structure, ARs display 
the topology typical of GPCRs. Sequence comparison between the different GPCRs revealed 
the existence of different receptor families sharing no sequence similarity even if specific 
fingerprints exist in all GPCR classes. However, all these receptors have in common a central 
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core domain consisting of seven transmembrane helices (TM1-7), with each TM composed of 
20–27 amino acids, connected by three intracellular (IL1, IL2, and IL3) and three 
extracellular (EL1, EL2, and EL3) loops. Two cysteine residues (one in TM3 and one in 
EL2), which are conserved in most GPCRs, form a disulfide link which is possibly crucial for 
the packing and for the stabilization of a restricted number of conformations of these seven 
TMs. Aside from sequence variations, GPCRs differ in the length and function of their N-
terminal extracellular domain, their C-terminal intracellular domain, and their intracellular 
loops. Each of these domains provides very specific properties to these receptor proteins. 
Particularly, consensus sites for N-linked glycosylation exist on the extracellular regions of 
ARs, although the precise location of the sites for this post-translational modification varies 
amongst the AR subtypes. The carboxyl-terminal tails of the A1AR, A2BAR, and A3AR, but 
not A2AAR, possess a conserved cysteine residue that may putatively serve as a site for 
receptor palmitoylation and permit the formation of a fourth intracellular loop (Moro et al., 
2005). The A1AR, A2BAR, and A3AR are very similar in regard to the number of amino acids 
composing their primary structure, and in general, these AR subtypes are among the smaller 
members of the GPCR family. For example, the human homologs of the A1AR, A2BAR, and 
A3AR consist of 326, 328, and 318 amino acid residues, respectively. Conversely, the human 
A2AAR is composed of 409 amino acids. It should be noted that the size of ARs deduced from 
their primary amino acid structure frequently is not consistent with the mass estimated by 
polyacrylamide gel electrophoresis of the expressed proteins. The post-translational 
glycosylation of ARs, which may vary in a cell type-dependent fashion, likely accounts for 
these discrepancies. The human A1AR and human A3AR display 49% overall sequence 
identity at the amino acid level, while the human A2AAR and human A2BAR are 45% identical 
(Fredholm et al, 2001).  
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A1 adenosine receptors 
A1 receptors were purified in several species including man, rat, bovine, rabbit. The human A1 
receptor gene is localised on the chromosome 1q32 and codes for a 326 amino acid protein with a 
molecular weight of ~ 36.7 kDa (Olah and Stiles, 1995; Townsend-Nicholson et al., 1995). This 
receptor subtype has one or two glycosylation sites on the second extracellular domain, a potential 
site for acetylation of fatty acids on the carboxyl tail, several phosphorylation sites and a cluster of 
serine and threonine residues on the C-terminal portion (Linden, 1991). Molecular biology 
techniques demonstrated that the A1 receptors throught the interaction with Gi or Go proteins 
mediate the inhibition of adenylate cyclase, but can also inhibit G protein-coupled activation of 
voltage dependent Ca2+ channels and induced PLC activation (Stiles, 1992) (Figure 3). 
 
 
 
  
 
 
 
 
 
 
Figure 3: Adenosine A1 receptor and its signal transduction pathway 
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A1 adenosine receptor also determines the activation of the family of extracellular signal-regulated 
kinase 1/2 (ERK 1/2) (Fredholm et al., 2001a). Adenosine A1 receptors are widely expressed in both 
central nervous system (CNS) and peripheral tissues (Schindler et al., 2005). In the CNS, they are 
present in both pre- and post-synaptic regions. The highest density was found in the cortex, 
cerebellum and hippocampus. In the heart, adenosine A1 receptors predominate in the myocardium 
and in the sinus and atrioventicular nodes and are involved in responses that reduce oxygen demand 
by directly decreasing heart rate, force of contraction and conduction of action potential (through 
opening of K+-channels) as well as by indirect antiadrenergic effects (through inhibition of adenylyl 
cyclase). High levels of adenosine A1 receptors are observed in adipose tissue where its mediate a 
lipolytic action (Linden et al., 1991). Adenosine interacting with this receptor subtype posses the 
ability to reduce the free fatty acids in the blood; this advantageous aspect of adenosine could be 
useful for the treatment of type 2 diabetes. Adenosine A1 receptors are expressed in quite high 
density on the specialized cells of the thyroid, spinal cord, eye, adrenal gland, kidney, lung, pancreas 
and liver (Table 1).  
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Table 1: Effects mediated by A1 adenosine receptors 
 
 
DISTRIBUTION 
 
EFFECTS 
 
REFERENCES 
 
SNC 
 
 
Depression of excitotoxic neuronal 
damage  
Inhibition neurotransmitter release 
Neuroprotective effects 
 
Wardas, 2002 
 
Latini et al., 2001 
Liu et al., 2005 
 
HEART 
 
Anti-ischemic effects 
Beneficial effects on cardiac 
hypertrophy and heart function 
 
Roscoe et al., 2000 
Liao et al., 2003 
 
KIDNEY 
 
 
Inhibition of glomerular filtration rate 
Inhibition of renin secretion 
Increase of sodium reabsorbition 
 
Ren et al., 2001 
Schweda et al., 2005 
Gottlieb et al., 2002 
 
PANCREAS 
 
Increase of glucose uptake 
 
Xu et al., 1998 
 
AIRWAYS 
 
Bronchoconstriction 
 
Polosa, 2002 
 
ADIPOSE 
TISSUE 
 
Control of lipolysis 
 
Fruhbeck et al., 2001 
 
NEUTROPHILS 
 
 
Increase of chemotaxis, margination 
and endothelium adhesion  
Increase of phagocytosis and ROS 
release 
 
Gessi et al., 2000; Polosa, 2002 
 
Sullivan et al., 2001 
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A2 adenosine receptors 
A2 receptors are more widely distributed than A1 receptors, and are found in pre- and post-synaptic 
nerve terminals, mast cells, airway smooth muscle and circulating leukocytes (Polosa, 2002). A2 
receptors are subdivided into the A2A and A2B receptors, based on high and low affinity for 
adenosine, respectively. A2 receptors are coupled to the intracellular transduction pathway through 
Gs proteins and stimulates the activation of adenylate cyclase resulting in the elevation of 
intracellular cAMP (Olah and Stiles, 1995; Moreau and Huber, 1999) (Figure 4).  Activation of A2 
receptors also increases mitogen-activated protein kinase (MAPK) activity. Adenosine agonists 
through activation of ERK1/2 using the cAMP-ras-MEK1 pathway, exert mitogenic effects on 
human endothelial cells via the adenosine A2A subtype. However, the signaling pathways used by 
A2A receptor seem to vary with the cellular background and the signaling machinery of each cell. 
The adenosine A2B receptor subtype has been shown to activate not only ERK1/2 but also stress-
activated protein kinases (SAPK), such as p38 and jun-N-terminal kinase (JNK) (Fredholm et al., 
2001a). In most cell types the A2A subtype inhibits intracellular calcium levels whereas the A2B, via 
Gq proteins are linked with the stimulation of phospholipase C and induces calcium increase 
(Feostikov and Biaggioni, 1997). 
 
 
 
 
 
 
 
 
            
   Figure 4: Adenosine A2 receptor and their signal transduction pathways 
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A2A adenosine receptors 
A2A receptor gene has been localised to the chromosome 22q11.2 and codes for a 337 amino acid 
protein with a molecular weight of 45 kDa (Le, 1996; Moreau and Huber, 1999); A2A receptors are 
expressed in the central nervous system, vascular smooth muscle, endothelium and on neutrophils, 
platelets, mast cells and T cells (Gessi et al., 2000). It is well recognized that adenosine can exert 
powerful effects on the immune system; this molecule has been identified as an important 
endogenous immunosuppressing regulator as it has been demonstrated that the lack of the enzyme 
adenosine deaminase (ADA) is responsible for severe immunodeficient disease (Hirschhorn R., 
1995; Apasov et al., 1995). A number of effects ascribed to adenosine on lymphocyte function, such 
as inhibition of interleukin-2 (IL-2) production, cell proliferation and major histocompatibility 
complex-restricted cytotoxicity, appear to be mediated through Gs-coupled A2A receptors (Polmar et 
al., 1990). Moreover A2A adenosine receptors are expresses in human neutrophils were they inhibits 
the respiratory burst, assayed as superoxide anion production (O2-) from cells stimulated by the 
bacterial peptide N-formylmethionyl-leucyl-phenylalanine (FMLP) (Dianzani et al., 1994). Despite 
the beneficial aspects of quenching inflammation the described A2A adenosine receptors-mediated 
down-regulation of the immune response is potentially dangerous on its own. Indeed, the premature 
inhibition of immune cell function may allow pathogens to survive and as a result the overall 
damage to the organism will be greater. On the other hand, the lack of A2A adenosine receptors 
signaling may result in excessive damage with important biological consequences. Thus, a balance 
between the need to destroy invading pathogens and the desire to protect tissue from excessive 
damage may ultimately be dependent on the level of the activation of A2A receptors. Manipulation 
of inflammatory processes may include not only efforts to inhibit inflammation, but also the 
development of approaches to enhance local inflammatory processes (Table 2). 
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Table 2: Effects mediated by A2A adenosine receptors 
 
 
DISTRIBUTION 
 
EFFECTS 
 
REFERENCES 
 
SNC  
 
 
Protection against dopaminergic cell 
loss in Parkinson’s desease 
Increase acetylcholine, glutamate, 
aspartate, dopamine, and 
norepinephrine release   
 
Simon et al., 2008 
 
Riberio et al., 2000 
 
HEART 
 
 
Increase coronary flow 
Protection against ischemia-reperfusion 
injury  
 
Pacher et al., 2007 
Peart et al., 2007 
 
BLOOD VESSELS 
 
Coronary vasodilatation 
Inhibition of IL-6,IL-8, IL-12 
production 
 
Glover et al., 2001 
Haskò et al., 2000 
 
PLATELETS 
 
Inhibition of platelet aggregation  
 
Gessi et al., 2000 
 
IMMUNE CELLS 
 
Decrease of ROS release and cytotoxic 
activity 
Inhibition of neutrophils activation and 
O2-   production stimulated by fMLP 
Regulation of several cytokines 
production 
Inhibition of IL-2 production in 
lymphocytes 
 
Pierce et al., 2001 
 
Gessi et al., 2000 
 
McColl et al., 2006 
Erdmann et al., 2005 
 
MONOCITES/ 
MACROPHAGES 
 
Inhibition of TNF-α, IL-6, IL-8 and  
IL-10 production 
 
Haskò et al., 2000 
Ryzhov et al., 2008  
 
LUNGS 
 
Ant-inflammatory effects 
 
Fozard et al., 2002 
 
LIVER 
 
Reduction of hepatic ischemia 
reperfusion injury  
 
Lappas et al., 2006 
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A2B adenosine receptors 
The A2B receptor, although structurally closely related to the A2A receptor and able to activate 
adenylate cyclase, is functionally very different. It has been postulated that this subtype may utilise 
signal transduction systems other than adenylate cyclase because of these functional differences 
(Polosa, 2002). The A2B receptors, on the contrary with the other adenosine receptor subtypes, are 
characterized by a low density and it needs high adenosine levels to their activation. (Fredholm et 
al., 2001b).  The human A2B receptor gene has been localised to the chromosome 17p11.2-p12 and 
codes for a 332 amino acid protein with a molecular weight of ~ 37.0 kDa (Olah and Stiles, 1995; 
Townsend-Nicholson et al., 1995).  
A2B adenosine receptor has been identified in several areas including in the brain, human bronchial 
epithelium, endothelial cells, muscle cells, neurons, glial cells, fibroblasts and mast cells (Gessi et 
al., 2006). A2B receptors, predominantly expressed in human microvascular cells, modulate 
expression of angiogenic factors (Feoktistov et al., 2002). The A2B adenosine receptor subtype 
appears to mediate the actions of adenosine to increase growth factor production (VEGF) and cell 
proliferation of human retinal endothelial cells (HREC). Adenosine activates the A2B adenosine 
receptor in HRECs, which may lead to neovascularization by a mechanism involving increased 
angiogenic growth factor expression (Grant et al., 1999). On this light, A2B adenosine receptor 
inhibition may offer a way to inhibit retinal angiogenesis and provide a novel therapeutic approach 
to treatment of diseases associated with aberrant neovascularization, such as diabetic retinopathy 
and retinopathy of prematurity (Grant et al., 2001). Adenosine causes inhibition of cardiac 
fibroblasts growth and of vascular smooth muscle cells by activating A2B adenosine receptors 
(Dubey et al., 1999, 2000, 2001). Exogenous and endogenous adenosine inhibits both collagen 
production and cellular hypertrophy induced by fetal calf serum, most likely via A2B receptors 
(Dubey et al., 1998). Thus, A2B adenosine receptors may play a critical role in regulating cardiac 
remodeling associated with cardiac fibroblasts proliferation. Pharmacological or molecular 
biological activation of A2B adenosine receptors may prevent cardiac remodeling associated with 
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hypertension, myocardial infarction, and myocardial reperfusion injury after ischemia.  It is 
interesting to note that, in contrast to smooth muscle cells, A2B receptors induce growth of 
endothelial cells (Sexl et al., 1995; Grant et al., 1999). Even if A2B receptor stimulation improves 
the cell proliferation of peripheral microvessels and exerts opposite effect on cardiac tissue and 
capillaries, we can hypothesize that, as consequence of this ability to promote the endothelial cell 
proliferation, A2B may contribute to tumor growth and spreading by inducing neovascularization in 
the area surrounding the tumor masses. Moreover A2BARs have been implicated in the regulation 
of mast cell secretion  and, gene expression, intestinal function, neurosecretion, vascular tone and 
in particular asthma (Varani et al., 2005) (Table 3). 
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Table 3: Effects mediated by A2B adenosine receptors 
 
 
DISTRIBUTION 
 
EFFECTS 
 
REFERENCES 
 
SNC 
 
 
IL-6 release from astrocytes and 
protection during CNS injury 
 
Haskò et al., 2005 
 
HEART 
 
 
Inhibition of cardiac fibroblasts 
growth 
 
Dubey at al., 2000, 2001 
 
BLOOD VESSELS 
 
 
Vasodilatation 
Inhibition of ICAM-1 and  
E-selectin expression 
Prevention endothelial cell-
mediated inflammatory events  
Promotion of angiogenesis  
 
Yang et al., 2006 
 
 
Grant et al., 2001 
 
Feoktistov et al., 2002 
 
INTESTINAL 
EPITHELIAL CELLS 
 
Regulation Cl− secretion  
Release of IL-6 
 
Kolachala et al., 2008 
Sitaraman et al., 2001 
 
MAST CELLS 
 
 
Increase of degranulation, 
histamine release and IL-8 
secretion 
 
Polosa et al., 2006 
 
AIRWAYS 
 
Increase of IL-6, IL-19, TNF-α 
production 
 
Zhong et al., 2004, 2006 
 
 
MONOCITES/ 
MACROPHAGES/ 
NEUTROPHILS/ 
LYMPHOCYTES 
 
 
Down-regulation of IFN-γ-induced 
MHC class II expression and 
inducible nitric oxide synthase 
production (iNOS)   
Inhibition of monocyte colony 
stimulating factor (M-CSF)-
induced macrophage proliferation 
 
Xaus et al., 1999 
 
 
 
Gessi et al., 2005 
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A3 adenosine receptors 
The human A3 receptor gene has been localised to the chromosome 1p13.3 and consists of a 337 
amino acid protein with a molecular weight of 36.0 - 37.0 kDa (Olah and Stiles, 1995; Moreau and 
Huber, 1999; Atkinson et al., 1997). In comparison with the other adenosine receptors, the A3 
receptor exhibits large differences in structure, tissue distribution and its functional and 
pharmacological properties among species (Linden, 1994). The various effects of A3 receptor 
agonists, in vitro and in vivo, seem to be dual and opposite, depending on the level of receptor 
activation (Jacobson et al., 1998). The A3AR mRNA is being expressed in testis, lung, kidneys, 
placenta, heart, brain, spleen, liver, uterus, bladder, jejunum, proximal colon and eye of rat, sheep 
and humans. However, marked differences exist in expression levels within and among species. In 
particular rat testis and mast cells express high concentrations of A3AR mRNA, while low levels 
have been detected in most other rat tissues (Gessi et al., 2008). Lung and liver have been found as 
the organs expressing high levels of A3AR mRNA in human, while low levels have been found in 
aorta and brain. Lung, spleen, pars tuberalis and pineal gland expressed the highest levels of A3AR 
mRNA in sheep. The presence of A3AR protein has been evaluated through radioligand binding, 
immunoassay or functional assay in a variety of primary cells, tissues and cell lines (Gessi et al., 
2008). In the mouse brain a widespread, relatively low level of A3AR binding sites was found 
(Jacobson et al., 1993). Similar data were obtained in the rat and in gerbil and rabbit brain. 
Electrophysiological and biochemical evidence suggested the presence of A3ARs in the rat 
hippocampus and cortex, and functional studies also indicated its presence in the brain. In 
cardiomyocytes, there was no direct evidence of the presence of A3ARs  but several studies reported 
that it was responsible for cardioprotection in a variety of species and models, including isolated 
cardiomyocytes and isolated myocardial muscle preparations (Peart and Headrick, 2007). In lung 
parenchyma and in human lung type 2 alveolar-like cells (A549), the A3AR was detected through 
radioligand binding and immunohistochemical assays (Varani et al., 2006). The classical pathways 
associated with A3AR activation are the inhibition of adenylyl cyclase activity, through the coupling 
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with Gi proteins, and the stimulation of PLC, inositol triphosphate (IP3) and intracellular calcium, 
via Gq proteins (Fredholm et al., 2001) (Figure 5). However, more recently additional intracellular 
pathways have been described as relevant for A3AR signaling. For example, in the heart, A3AR 
mediates cardioprotective effects through ATP-sensitive potassium (KATP) channel activation. 
Moreover, it is coupled to activation of RhoA and a subsequent stimulation of phospholipase D 
(PLD), which in turn mediates protection of cardiac myocytes from ischemia (Mozzicato et al., 
2004). In addition, in different recombinant and native cell lines, A3AR is involved, like the other 
adenosine subtypes, in the modulation of MAPK activity (Schulte and Fredholm, 2003). A3AR 
signaling in Chinese Hamster Ovary cells transfected with human A3AR (CHO-hA3) leads to 
stimulation of extracellular signal-regulated kinases (ERK1/2). In particular, A3AR signaling to 
ERK1/2 depends on βγ release from pertussis toxin (PTX)-sensitive G proteins, phosphoinositide 3-
kinase (PI3K), Ras and mitogen-activated protein kinase kinase (Schulte and Fredholm, 2003). 
Recently, it has been shown that A3AR activation leads to an increase in c-Jun N-terminal kinase 
(JNK) phosphorylation in U87MG glioblastoma cells (Gessi et al., 2010). It has been reported that 
A3AR activation is able to decrease the levels of PKA, a downstream effector of cAMP, and of the 
phosphorylated form of PKB/Akt in melanoma cells. This implies the deregulation of the Wnt 
signaling pathway, generally active during embryogenesis and tumorigenesis to increase cell cycle 
progression and cell proliferation (Fishman et al., 2002). Involvement of the PI3K/PKB pathway 
has been linked with preconditioning effects induced by A3AR activation in cardiomyocytes from 
newborn rats (Germack and Dickenson, 2005). Subsequently it has been demonstrated that CREB 
phosphorylation occurs through both Akt-dependent and -independent signaling. Activation of 
PI3K-Akt-pBAD by A3AR has been observed recently in glioblastoma cells leading to cell survival 
in hypoxic conditions (Merighi et al., 2007). Further studies indicate that A3AR activation by 
interfering with PKB/Akt pathways can decrease interleukin-12 (IL-12) production in human 
monocytes (la Sala et al., 2005). Collectively, these findings demonstrate that several intracellular 
mechanisms are involved following A3AR stimulation, the understanding of which may be essential 
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and crucial for explaining the different aspect of its activation (Table 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Schematic representation of intracellular pathways coupled to adenosine A3 
receptors  
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Table 4: Effects mediated by A3 adenosine receptors 
 
 
DISTRIBUTION 
 
 
EFFECTS 
 
REFERENCES 
 
SNC 
 
 
Reduction in the degree of spontaneous 
apoptotic cell death 
Neuro-protective effect in epilepsy, 
trauma and brain ischemia 
 
Abbracchio et al., 1998 
 
Abbracchio et al., 1999 
 
HEART 
 
Protection of myocytes from ischemia 
 
Mozzicato et al., 2004 
 
MAST CELLS 
 
Antigen-mediated mast cell 
degranulation. 
 
Fredholm et al., 2001 
 
IMMUNE CELLS 
 
 
Eosinophils: inhibition of degranulation 
Neutrophils: inhibition of oxidative burst 
and degranulation 
Monocytes: inhibition of superoxide 
anion generation; suppression of TNF-α 
and IL-12 release  
Mast cells: release of allergic mediators 
 
Fossetta et al., 2003 
Gessi et al., 2002 
 
Broussas et al., 1999 
La Sala et al., 2005 
 
Gessi et al., 2004a 
 
LUNG 
 
Inhibition of degranulation and O2- 
release in eosinophils  
 
Ezeamuzie et al., 1999 
 
 
TUMOR CELLS 
 
Inhibition of tumour growth 
Inhibition of A375 human cells 
proliferation 
Stimulation of glioblastoma cell survival 
in hypoxic conditions 
 
Gessi et al., 2004b 
Merighi et al., 2005 
 
Merighi et al., 2007 
 
 
 
 
 
 - 23 -
Therapeutic potential 
 
Adenosine and cardiovascular system 
A1AR is the most extensively studied and well characterized of the adenosine receptor subtypes in 
relation to cardiac protection. The A1AR is best understood insofar for its effects on injury and in 
terms of receptor-coupled kinase/protein signaling. Originally, adenosine (via A1AR activation) 
was thought to induce myocardial protection through preservation of ATP (and improved 
nucleotide repletion on reperfusion), stimulation of glycolysis, and normalization of the hearts so-
called “oxygen supply/demand ratio” (Ely and Berne, 1992). Subsequent investigations have 
identified essential protein kinase signaling cascades together with putative end-effectors 
(including the mitochondrial KATP channel), in the protective and preconditioning actions of 
A1ARs. 
Adenosine enhances tolerance to ischemia via metabolic substrate effects (Headrick et al., 2003). 
Adenosinergic cardioprotection in ischemic-reperfused hearts involves reductions in oncotic and 
apoptotic death, and improved functional outcomes (Willems et al., 2005). Recent work supports 
differential effects of acute adenosine vs. transient adenosinergic preconditioning, consistent with 
multiple pathways of protection (Peart and Headrick, 2003). In terms of cellular targets, adenosine 
appears to directly protect cardiomyocytes or myocardial tissue (likely via A1 and A3ARs), and 
additionally protects via limiting inflammation and injurious interactions between inflammatory 
cells and vascular and myocardial tissue. The different cardioprotective effects of AR agonism 
have been verified in animal and human tissue (Willems et al., 2005). However, few studies have 
addressed the possibility that altered AR-mediated protection might underlie specific 
cardiovascular disorders, though there is evidence to support this. Hypertrophic hearts, for 
example, display abnormal adenosinergic signaling, and dysregulated adenosine formation. 
Interestingly, ARs impact on many processes implicated in cardiovascular "aging", regulating Ca2+ 
influx and oxidant injury, substrate metabolism, angiogenesis, myocardial fibrosis, and apoptotic 
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processes (Willems et al., 2005). Given evidence of a role for ARs in intrinsic cardioprotection, 
mediation of preconditioning, and modifying the above-mentioned processes, alterations in AR 
signalling could contribute both to ischemic intolerance and emergence of other features of aged 
myocardium. All ARs are considered to be expressed within cardiovascular cells. Studies in 
different species verify endogenous adenosine contributes to intrinsic ischemic tolerance, and 
support cardioprotective roles for A1ARs in vitro and in vivo, and for A2AARs in vivo (Willems et 
al., 2005). Anti-ischemic effects of A1ARs appear direct (at cardiomyocytes), since similar 
protection is observed in isolated hearts, cardiomyocytes, and in vivo (Roscoe et al., 2000). 
Protective A2AAR effects involve modulation of vascular function, platelet adhesion and neutrophil 
activation. There is currently no direct evidence for acute A2BAR mediated cardioprotection, 
partially due to lack of selective A2BAR agonists/antagonists. In contrast to A1 and A2AARs, there 
is little evidence that intrinsically activated A3ARs mediate protection. A3AR antagonists have no 
effect on ischemic outcomes in myocytes or hearts (Maddock et al., 2002). 
 
Adenosine and inflammation  
The adenosine receptor system has evolved as both a rapid sensor of tissue injury and the major 
‘first-aid’ machinery of tissues and organs (Haskò et al., 2008). Adenosine receptor activation thus 
preserves tissue function and prevents further tissue injury following an acute injurious insult, such 
as reperfusion injury, actions in which the immune system has a paramount role. This primordial 
protective function of the adenosine receptor system following acute insults can, however, be 
overshadowed by its reduced ability to protect against chronic insults. In addition, in certain chronic 
disease states, such as asthma, the adenosine receptor system can even exacerbate tissue dysfunction 
(Haskò et al., 2008).   
The effect of adenosine on cytokine production by macrophages has attracted considerable attention, 
because macrophage-derived cytokines are crucial initiators and orchestrators of immune responses. 
As tumour necrosis factor α (TNF-α) was one of the first cytokines to be discovered, a substantial 
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body of information has accumulated regarding the ability of adenosine receptor activation to limit 
TNF-α production following macrophage activation. Recent studies using adenosine-receptor 
knockout mice have painted a detailed but still no complete picture of the receptors involved. 
Several studies agree that the A2A receptor is the primary and dominant adenosine receptor subtype 
that mediates inhibition of TNF-α (Haskò et al., 2000; Kreckler et al., 2006; Ryzhov et al., 2008). A 
role for other receptors was postulated based on the observation that adenosine, and the agonists 
NECA and IB-MECA (CF-101) can each inhibit, albeit to a lesser extent, TNF-α production even in 
A2A-receptor knockout mice (Haskò et al., 2000; Kreckler et al., 2006). A study using a combined 
approach of using A2A receptor knockout mice and the A2B receptor antagonist MRS 1754 supports a 
role for A2B receptors as the other inhibitory receptor (Kreckler et al., 2006). However, it appears 
that A2B receptors become operational only when their effect is not masked by A2A receptors, 
because both MRS 1754 and genetic deletion of A2B receptors in the presence of functional A2A 
receptors fails to affect the suppression of TNF-α production (Kreckler et al., 2006; Ryzhov et al., 
2008). 
Adenosine is also a potent modulator of neutrophil function and it has long been appreciated that 
adenosine, by activating its receptors, regulates stimulated production of reactive oxygen species by 
these cells and phagocytosis (Cronstein et al., 1983, 1985; Varani et al., 1998).  Individual 
neutrophils do not produce large quantities of cytokines; however, because of the large numbers of 
accumulated neutrophils the cumulative contribution to pro-inflammatory cytokine levels at a given 
site is large. Adenosine, acting at A2A receptors, regulates the production of a range of cytokines 
including TNF-α, macrophage inflammatory protein (MIP)-1α (also known as CCL3), MIP-1β 
(CCL4), MIP-2α (CXCL2) and MIP-3α (CCL20) (McColl et al., 2006). Neutrophils are recruited to 
inflammatory sites by the post-capillary venular endothelium, which alters the expression of 
adhesive molecules on its surface to capture neutrophils from the circulation. Adenosine, via A2A 
receptors, inhibits the adhesion of neutrophils to the endothelium by decreasing the expression and 
stickiness of the adhesion molecules expressed on neutrophils (Cronstein et al., 1992; Sullivan et al., 
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2004; Zhao et al., 1996). By contrast, A1 receptors promote neutrophil adhesion to different adhesive 
molecules on the endothelium and on other surfaces (Cronstein et al., 1992). Once in the tissue 
neutrophils migrate along gradients of chemoattractants. In addition, neutrophils cluster their A3 
receptors at the leading edge of the cell and release ATP, which is converted at the cell surface to 
adenosine, which then acts in an autocrine manner to stimulate migration (Chen et al., 2006). At 
inflamed sites neutrophils undergo apoptosis and adenosine, acting at A2A receptors, prevents 
neutrophils from undergoing apoptosis (Mayne et al., 2001; Walker et al., 1997; Yasui et al., 2000). 
Thus, virtually every function carried out by neutrophils is regulated by adenosine and its receptors. 
In addition to regulating lymphocyte function indirectly by stimulating adenosine receptors on 
innate immune cells such as dendritic cells, adenosine can also directly affect lymphocyte responses 
by binding and activating adenosine receptors on lymphocytes. A number of recent studies using 
adenosine-receptor-knockout mice have evaluated the effect of adenosine receptor activation on 
various lymphocyte functions. The consensus emerging from these studies, as well as 
pharmacological studies, is that A2A receptors are the dominant adenosine receptors in dictating 
lymphocyte responses. Similar to CD4+ cells, adenosine inhibits IL2 production by both polarized 
type 1 cytotoxic T (TC1) and TC2 CD8+ cells, the effect of which was proposed to proceed through 
A2A receptors based on pharmacological evidence (Erdmann et al., 2005). However, the production 
of neither TC1 (IFN-γ) nor TC2 (IL4 and IL5) cytokines was influenced by A2A receptor activation. 
In addition, pharmacological A2A receptor activation failed to reduce TC1 or TC2 cell cytolytic 
function (Erdmann et al., 2005), which suggests that another subtype, possibly the A3 receptor, may 
mediate the anti-cytotoxic effect of adenosine noted in prior studies (Koshiba et al., 1997; Hoskin et 
al., 2002). Indeed the expression of A3 receptors in CD4+ and CD8+ cells is up-regulated after T 
cells activation with phytohemagglutinin (PHA) (Gessi et al., 2004a). In contrast to these results 
with CD8+ cytotoxic cells, recent data with A1-, A2A- and A3-receptor-knockout mice support a 
primary role for A2A receptors in preventing the cytolytic activity of IL2-activated natural killer 
(NK) cells (Raskovalova et al., 2005). In conclusion lymphocyte function is potently regulated by 
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A2A receptors, suggesting that the anti-inflammatory effects of A2A receptor agonists in animal 
models of autoimmunity and ischaemia are mediated, in part, by targeting lymphocytes. 
 
Adenosine and airways 
A role for adenosine in pulmonary disease was first suggested when it was found that adenosine 
and related synthetic analogues were potent enhancers of IgE-dependent mediator release from 
isolated rodent mast cells (Holgate et al., 1980). A few years later, adenosine administered by 
inhalation was shown to be a powerful bronchoconstrictor of asthmatic but, importantly, not of 
normal airways (Cushley et al., 1983). Further work showed that both allergic and non-allergic 
asthmatics responded in a similar way and that the effect was also seen with adenosine 5′-
monophosphate (AMP), ADP and ATP (Basoglu et al., 2005). Elevated levels of adenosine are 
present in chronically inflamed airways; they have been observed both in the bronchoalveolar 
lavage fluid and the exhaled breath condensate of patients with asthma (Caruso et al., 2006). 
Adenosine levels are also increased after allergen exposure and during exercises in atopic 
individuals. The observed increase in tissue levels of adenosine suggests that adenosine signaling 
could regulate important features of chronic inflammatory disorders of the airways, including 
asthma and chronic obstructive pulmonary disease (COPD). Consistent with the hypothesis of 
adenosine playing an important role in the pathogenesis of chronic inflammatory disorders of the 
airways, mice deficient in adenosine deaminase (ADA) develop severe pulmonary inflammation 
and airway remodeling in association with elevated adenosine concentrations in the lung 
(Blackburn et al., 2000). The pulmonary phenotype in ADA-deficient mice consists of airway 
accumulation of eosinophils and activated macrophages, mast cell degranulation, mucus 
metaplasia in the bronchial airways, and emphysema-like devastation of the lung parenchyma. 
Although these histological traits do not completely resemble those of human asthma, the ADA-
deficient mouse model is a useful tool to study the pathogenic role of adenosine in chronic airway 
inflammation.  The central role of adenosine in chronic lung inflammation is also supported by 
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studies carried out in mice that have increased levels of interleukin IL-13 in the lung. These mice 
develop inflammation, fibrosis and alveolar destruction in association with elevated adenosine 
concentrations in the lung (Caruso et al., 2006). Treatment with ADA to prevent the increase in 
adenosine concentrations resulted in a marked decrease in the severity of the pulmonary 
phenotype, suggesting that adenosine mediates IL-13-induced inflammation and tissue remodeling. 
Blockade of adenosine re-uptake by administration of dipyridamole has been used in humans to 
test the hypothesis that the accumulation of extracellular adenosine functionally modulates 
important features of the asthmatic response. In addition, it has been shown that a rapid increase in 
sputum eosinophilia occurs when asthmatics are exposed to adenosine by means of a provocation 
test with AMP (van der Berge et al., 2003). Taken together, these observations indicate that 
adenosine is likely to play an important role in asthma and COPD through interaction with specific 
cell-surface receptors. Expression of the four identified adenosine receptors has been shown in a 
large number of proinflammatory and structural cells and recently in the peripheral lung 
parenchyma of patients with COPD. The affinity of A1, A2A, and A3ARs, studied by means of 
saturation binding assays, was substantially decreased in patients with COPD, whereas their level 
of expression appears to be increased. Conversely, the affinity of A2BARs was not altered, but the 
density was significantly decreased in patients with COPD (Varani et al., 2006). This suggests that 
adenosine signalling play an important but rather complex role in COPD. Hence, adenosine 
responses are not only dictated by the bioavailability of the nucleoside but also by the pattern of 
adenosine receptor expression, which is known to be finely modulated by physiological and/or 
pathological tissue environments. Stimulation of A1ARs promotes activation of human neutrophils 
and enhances neutrophil adhesion to the endothelium in vitro, suggesting a pro-inflammatory role 
for this receptor (Cronstein et al., 1985, 1990, 1992). However, in ADA/A1ARs double knockout 
mice, the lack of A1ARs results in enhanced pulmonary inflammation, mucus metaplasia, alveolar 
destruction and earlier death from respiratory distress, indicating a protective function. Activation 
of A2AARs on activated immune cells by adenosine appears to largely suppress the inflammatory 
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response. In human neutrophils, stimulation of A2AARs reduces neutrophil adherence to the 
endothelium, inhibits formyl-Met-Leu-Phe (fMLP)-induced oxidative burst and inhibits superoxide 
anion generation (Fredholm et al., 1996). In monocytes and macrophages, activation of A2AARs 
inhibits lipopolysaccharide-induced tumour necrosis factor-α expression. Therefore, A2AAR 
agonists might have anti-inflammatory effects in diseases such as COPD, where neutrophil- and 
monocyte-mediated tissue injury is implicated (Caruso et al., 2006). Initial evidence for the role of 
A2BARs in asthma and COPD came from pharmacological studies of enprofylline, a 
methylxanthine structurally related to theophylline (Feoktistov and Biaggioni, 1995). It was 
proposed that the A2BAR might be the therapeutic target in the long-term clinical benefit achieved 
with relatively low doses of theophylline and enprofylline. Recently, A2BARs have been shown to 
mediate several pro-inflammatory effects of adenosine in the large majority of inflammatory and 
structural cells of the lung. For example, functional human A2BARs have been identified in mast 
cells, bronchial smooth muscle cells and lung fibroblasts. In these cells, adenosine, via activation 
of A2BARs, increases the release of various inflammatory cytokines, which induce IgE synthesis 
from human B lymphocytes and promote differentiation of lung fibroblasts into myofibroblasts. 
Such findings provide support for the view that activation of A2BARs could enhance the 
inflammatory response associated with asthma and that selective blockade of these receptors 
would be potentially beneficial in the treatment of asthma and other pulmonary inflammatory 
diseases. The functional significance of the A3AR in the pathogenesis of chronic inflammatory 
airway diseases remains controversial largely owing to major species differences (Caruso et al., 
2006).  
 
Adenosine and cancer 
One of the difficulties in treating most of the common cancers (colon, lung, breast, prostate, etc.) is 
that they form solid tumors. The individual cancer cells, being different from normal cells, form a 
tissue mass that behaves in a radically different way from normal tissues in the body. This is 
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because the major cell population (the cancer cells) has grown in a way that is out of step with all 
of the other cells that would normally form a supportive network. In particular, the growth of the 
cancer is not coordinated with the development of a proper blood supply. The vascular network of 
a tumor is usually inadequate, the blood vessels are often too few in number, the network is 
improperly branched, and their calibre is not well controlled. This means that the blood supply is 
inadequate. Consequently, most solid tumors do not receive sufficient oxygen and the cells are 
hypoxic. Specifically, hypoxia is conducive to adenine nucleotide breakdown, which is responsible 
for the adenosine release (Vaupel et al., 2001). As a consequence, adenosine accumulates to high 
levels in hypoxic tissues. In particular, it is recognized that significant levels of adenosine are 
found in the extracellular fluid of solid tumors, suggesting a role of adenosine in tumor growth 
(Merighi et al., 2003). Adenosine, released from hypoxic tissue, is thought to be an angiogenic 
factor that links altered cellular metabolism, caused by oxygen deprivation, to compensatory 
angiogenesis. Angiogenesis (or neovascularization) begins with the migration of endothelial cells, 
originating from capillaries, into the tissue being vascularized. Adenosine has been reported to 
stimulate or inhibit the release of angiogenic factors depending on the cell type examined 
(Burnstock, 2006). On one hand, adenosine is known to cause the synthesis of vascular endothelial 
growth factor (VEGF) and increase the proliferation of endothelial cells obtained from the aorta, 
coronary vessels, and retina (human retinal endothelial cells, HREC). In particular, adenosine has 
been shown to induce the DNA synthesis in cultures of human umbilical vein endothelial cells 
(HUVEC) (Burnstock, 2006).  
In the human leukemia HL60, human melanoma A375, and human astrocytoma cells, adenosine at 
millimolar concentrations caused apoptosis. It seems likely that apoptosis is mediated by the 
intracellular actions of adenosine rather than through surface receptors (Merighi et al., 2002). It has 
been argued that the effect of high adenosine concentration might be subsequent to uptake of 
adenosine by the cell and intracellular accumulation of AMP, leading to caspase activation 
(Merighi et al., 2003). 
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In many cases, tumor-induced immune suppression is mediated by soluble inhibition factors or 
cytokines elaborated by the tumor cells. Extracellular fluid of solid carcinomas contains 
immunosuppressive concentrations of adenosine, suggesting that this autacoid constitutes an 
important local immunosuppressant within the microenvironment of solid tumors. 
Antigen-presenting cells such as dendritic cells and macrophages are specialized to activate naïve 
T-lymphocytes and initiate primary immune responses. Adenosine inhibits interleukin-12 (IL-12) 
and tumor necrosis factor-α production in dendritic cells and in macrophages impairing T-cell 
priming and suppressing the anticancer immune response. Furthermore, adenosine impairs the 
induction and expansion of cytotoxic T-lymphocytes and the antitumor activity of natural killer 
(Hoskin et al., 2002). 
Differential effects of adenosine on normal and cancer cells have been previously reported, 
showing that the proliferation of lymphocytes derived from patients with chronic lymphocytic 
leukemia was inhibited by adenosine, whereas the proliferation of lymphocytes from healthy 
people was inhibited to a lesser extent. In vivo studies have shown that adenosine exerts a 
profound inhibitory effect on the induction of mouse cytotoxic T-cells, without substantially 
affecting T-cell viability (Hoskin et al., 2002). Adenosine sustains a complex role in the immune 
system activity, because when given to mice pretreated with cyclophosphamide it demonstrated a 
myeloprotective effect by restoring the number of white blood cells and the percentage of 
neutrophils as compared with normal values. Furthermore, it has been demonstrated that the 
elevation of the extracellular adenosine concentrations induced a radioprotective effect in mice by 
the stimulation of hematopoiesis in the bone marrow and the spleen. In support of this 
myelostimulatory role, it has been demonstrated that adenosine enhances cycling of the 
hematopoietic progenitor cells (Pospísil et al., 2001). 
The ability of adenosine to specifically inhibit tumor cell growth in vitro and in vivo suggests that 
the activation and/or blockade of the pathways downstream of adenosine receptors may contribute 
to tumor development. Furthermore, the extracellular adenosine concentration may be a crucial 
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factor in determining the cell progression pathway, either in the apoptotic or in the cytostatic state 
(Merighi et al., 2003). 
Adenosine accumulates at high levels in hypoxic regions of solid tumours, and several lines of 
evidence indicate that the A3 receptor is overexpressed in several solid tumors suggesting that it 
may be a tumor marker (Gessi et al., 2004b). Furthermore it has been reported that it plays a 
pivotal role in the adenosine-mediated inhibition of tumour cell proliferation (Merighi et al., 2005). 
Therefore clinical trials have demonstrated the possibility of using A3 agonists for treatment of 
cancer (Fishman et al., 2002). 
 
Adenosine and central nervous system 
Adenosine levels in the brain extracellular space increase dramatically during metabolically 
stressful conditions, such as ischemia, seizures, or trauma. Adenosine, acting via its receptors, 
modulates excitability in the central nervous system (CNS) and has a role in mechanisms of seizure 
susceptibility, sleep induction, basal ganglia function, pain perception, cerebral blood flow,  and 
respiration (Benarroch, 2008).  
Adenosine functions as a natural sleep-promoting agent accumulating during periods of sustained 
wakefulness and decreasing during sleep. It was suggested that adenosine participates in resetting 
of the circadian clock by manipulations of behavioural state. Indeed, A1ARs of the suprachiasmatic 
nucleus regulate the response of the circadian clock to light (Elliott et al., 2001). The sleep 
inducing properties of adenosine is in line with its A1AR-mediated inhibitory action and may 
involve multiple neuronal populations in the central nervous system; however, the actions upon the 
basal forebrain nuclei involved in sleep and arousal appear to be particularly important (Ribeiro et 
al., 2002).  
In healthy humans, caffeine inhibits psychomotor vigilance deficits from sleep inertia, a ubiquitous 
phenomenon of cognitive performance impairment (van Dongen et al., 2001). It thus emerges that 
there exists a potential role of adenosine-related compounds and of A1AR agonists as sleep 
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promoters and adenosine receptor antagonists as arousal stimulators. Adenosine A1AR agonists 
have anxiolytic activity in rodent models of anxiety, whereas caffeine and the adenosine A1AR 
selective antagonist, cyclopentyltheophylline, have anxiogenic properties. In accordance with the 
notion that synaptic plasticity is the basis for learning and memory in different brain areas, 
adenosine correspondingly modulates behaviour in various learning and memory paradigms, and 
adenosine A1AR antagonists have been proposed for the treatment of memory disorders (Ribeiro et 
al., 2002). Cognitive effects of caffeine are mostly due to its ability to antagonise A1ARs in the 
hippocampus and cortex, the brain areas mostly involved in cognition, positive actions of caffeine 
on information processing and performance might also be attributed to improvement of 
behavioural routines, arousal enhancement and sensorimotor gating (Fredholm et al., 1999).  
One of the first pathophysiological roles proposed for adenosine was as an endogenous anti-
convulsant (Dragunow et al., 1986). Limitations of the use of adenosine receptor agonists as anti-
convulsant drugs are due to their pronounced peripheral side effects as well as central side effects, 
like sedation. 
Phase I clinical safety studies in healthy volunteers showed that intrathecal adenosine 
administration attenuated several types of experimental pain without causing significant side 
effects. Allosteric modulation of adenosine receptors, namely of A1ARs, has been attempted with 
success with the objective of developing drugs that by sinergising with endogenous adenosine 
action could have minimal side effects in the absence of adenosine. A further advantage of 
allosteric modulators is that they usually possess some degree of tissue selectivity. Allosteric 
modulation of adenosine A1ARs reduces allodynia, and, more interesting, the allosteric modulator 
T62 was effective not only after intrathecal injection but also after systemic administration, which 
reinforces the interest of adenosine-related compounds as putative drugs for the treatment of 
chronic pain associated with hyperalgesia and allodynia (Pan et al., 2001). A1AR agonists were 
conclusively shown to attenuate ischemic or excitotoxic neuronal damage both in vitro (cell 
cultures, brain slices) and in vivo in different models of ischemia/hypoxia (Wardas, 2002).  
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Studies in knockout mice or by using pharmacologic blockade indicate that A2AARs in the striatum 
modulate locomotor activity (Benarroch 2008). Activation of A2AARs results in increased GABA 
release in the globus pallidus, which would lead to disinhibition of the subthalamic nucleus 
(Ribeiro et al., 2002). The A2AARs are also coexpressed with A1ARs in glutamatergic 
corticostriate terminals and antagonize the presynaptic inhibitory effect of the A1ARs on glutamate 
release in the striatum. Epidemiologic and laboratory data suggest that caffeine may reduce the risk 
of Parkinson’s disease by preventing degeneration of nigrostriatal dopaminergic neurons. 
Furthermore, caffeine and selective A2AAR antagonists protect against dopaminergic cell loss in 
several toxin models of Parkinson’s disease (Simon et al., 2008).  
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AIM OF THE THESIS 
Adenosine is a potent extracellular messenger that is produced in high concentrations under 
metabolically unfavourable conditions, like hypoxia or ischaemia.  Tissue hypoxia, consequent to a 
compromised cellular energy status, is followed by the enhanced breakdown of ATP leading to the 
release of adenosine. Through the interaction with A1 and A2 membrane receptors, adenosine is 
devoted to the restoration of tissue homeostasis, acting as a retaliatory metabolite. Several aspects 
of the immune response have to be taken into consideration and even though in general it is very 
important to dampen inflammation, in some circumstances, such as the case of cancer, it is also 
necessary to increase the activity of immune cells against pathogens. Therefore, adenosine receptors 
that are defined as “sensors” of metabolic changes in the local tissue environment may be very 
important targets for modulation of immune responses and drugs devoted to regulating the 
adenosinergic system are promising in different clinical situations. 
The first studies aimed at elucidating the mechanisms by which the absence of ADA leads to 
immunodeficiency first suggested the presence of adenosine receptors on lymphocytes to suppress 
or dampen the immune response. Therefore, to understand the pathophysiological implications of 
adenosine-triggered effects in T cells we review the main actions attributed to adenosine by receptor 
subtype activation. Adenosine through the interaction with A2 and A3 receptors plays a crucial role 
in inflammation and in the regulation of immune cells. The most important therapeutic implication 
is that A2A receptors, proposed as “natural” brakes of inflammation, appear to represent a promising 
pharmacological target to treat a wide variety of diseases characterized by a strong 
immunoinflammatory component (chapter 1).  
Then we moved to discuss the involvement in inflammation of A3 adenosine receptor, that is evident 
from the large amount of experimental work carried out in peripheral blood cells of the immune 
system and in a variety of inflammatory conditions. Following a detailed analysis of the literature 
the A3 adenosine receptor subtype appears to play a complex role as both pro and anti-inflammatory 
effects have been demonstrated depending not only on the cell types investigated but also on the 
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model of inflammation used and the species considered. This chapter will discuss developments in 
our understanding of the role of adenosine A3 receptor activation in the function of the different 
types of cells of the immune system including neutrophils, eosinophils, lymphocytes, monocytes, 
macrophages and dendritic cells (chapter 2). 
Finally we have characterized the role of adenosine in atherosclerosis, a chronic inflammatory 
desease, in large part due to the accumulation of macrophage white blood cells and promoted by 
low-density lipoproteins (LDL). Adenosine released from ischemic and hypoxic tissues interacts 
with four extracellular G protein-coupled receptors, A1, A2A, A2B, and A3. All the four adenosine 
subtypes have been recently associated to the modulation of angiogenesis. Therefore due to the link 
between ado, inflammation and angiogenesis and the increasing evidence that these factors play a 
role in atherogenesis we thought to investigate HIF-1α, VEGF, IL-8 and FC formation by ado 
receptors in human macrophages and in an “in vitro” model of human FC (chapter 3). 
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Adenosine and lymphocyte regulation 
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Introduction 
Adenosine is an endogenous purine nucleoside that is constitutively present at low levels outside the 
cells but might dramatically increase its concentrations following metabolic stress conditions like 
those induced by hypoxia or ischaemia. After its release adenosine induces its biological effects 
through the interaction with four cell surface receptors classified by molecular, biochemical and 
pharmacological data into four subtypes: A1, A2A, A2B and A3 (Fredholm et al., 2001). Each of these 
receptors, with the exception of the A1 subtype, are expressed on human and mouse T lymphocytes 
and it appears that their activation represents a potent endogenous immunosuppressive pathway that 
regulates the excessive immune response against potent external insults. The interest in the 
immunomodulatory effects of adenosine arose after the discovery that hereditary deficiency of the 
enzyme adenosine deaminase (ADA) was associated with severe combined immune deficiency 
disease (SCID) (Hershfield, 2005). ADA converts adenosine to inosine and deoxyadenosine to 
deoxyinosine and its activity is greater in T cells in comparison with B cells or erythrocytes. ADA 
deficiency is one of the most severe immunodeficiencies due to the sensitivity of T cells to the 
accumulation of the ADA substrates adenosine and 2′-deoxyadenosine. SCID is a disease 
characterized by severe lymphocytopenia, affecting both B and cells, and a marked susceptibility to 
infection. The accumulation of adenosine and the activation of adenosine receptors in T cells may 
lead to the depletion of lymphocytes and impairment of their function (Buckley 2004; Hershfield, 
2004). Moreover, ADA deficiency in mice causes impairment of intrathymic T cell development 
and enhanced thymocyte apoptosis supporting the hypothesis that adenosine is responsible for 
depletion of T cells occurring in ADA SCID (Apasov et al., 2001). Indeed, the studies aimed at 
elucidating the mechanisms by which the absence of ADA leads to immunodeficiency first 
suggested the presence of adenosine receptors on lymphocytes to suppress or dampen the immune 
response (Wolberg et al., 1975). Therefore, to understand the pathophysiological implications of 
adenosine-triggered effects in T cells we intend to review the main actions attributed to adenosine 
by receptor subtype activation. 
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Adenosine metabolism and adenosine receptor activation under physiological 
and pathological conditions 
Adenosine has several physiological effects through the interaction with four known adenosine 
receptors, A1 and A3 that through the interaction with Gi/0 inhibit adenylyl cyclase activity, and A2A 
and A2B that increase cAMP production (a strong immunosuppressive agent) via Gs. In addition, 
they can modulate the activity of phospholipase C, D, A2, cGMP, K+ and Ca2+ channels and 
mitogenactivated protein kinases (MAPKs) regulating a variety of cellular effects (Fredholm et al., 
2001). It has been suggested that adenosine receptors act as “sensors” and that extracellular 
adenosine acts as a “reporter” of metabolic changes in the local tissue environment (Sitkovsky et 
al., 2005) Adenosine concentrations are normally regulated through its catabolism by ADA and 
through phosphorylation by adenosine kinase. In ADA deficiency the capacity of adenosine kinase 
is saturated and adenosine levels increase from 100–300 nM to 10 µM (Hershfield 2005), which 
could excessively stepwise activate all adenosine receptors. Moreover, an increase of intracellular 
adenosine inhibits the hydrolysis of S adenosylhomocysteine that is a potent inhibitor of 
transmethylation reactions. The lack of ADA leads also to the accumulation of deoxyadenosine, a 
product of DNA degradation, that in contrast to adenosine does not play a regulatory role in 
physiological conditions but determines an increase in deoxyATP that in turn inhibits DNA 
synthesis and activates apoptosis suggesting the possibility that deoxyadenosine itself may also 
have pathological effects (Hershfield 2005). Inflammatory tissue conditions are often associated 
with a low oxygen tension, or hypoxia, that is the cause of an associated production of adenosine in 
this environment. Therefore, the prevalent activity of 5’nucleotidase over activity of adenosine 
kinase (Decking 1997; Ledoux 2003) occurring in hypoxic conditions is responsible for a 
significant adenosine accumulation in sites of tissue injury (Lukashev et al., 2004). 5′Nucleotidase 
represents the major enzyme responsible for the extracellular production of adenosine from AMP 
and has a critical role in the functional activation of T cells. Deficiency of 5′nucleotidase activity 
has been associated with a number of immunodeficiency diseases, such as lymphoproliferative 
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disorders and systemic lupus erythematosus. Abnormal levels of these enzymes may be associated 
with an autoimmune pathology (Vivekanandhan et al., 2005). Therefore, under normal conditions 
adenosine, which is continuously produced intracellularly and extracellularly and maintained at low 
intracellular levels (about 100 nM) through the metabolic activity exerted by adenosine kinase and 
adenosine deaminase, interacts with the high-affinity A1 and A2A receptor subtypes. In ADA 
deficiency or in hypoxic, ischaemic or inflamed conditions, the intracellular production of 
adenosine is increased at very high micromolar concentrations and transported across cell 
membranes by specific agents finally leading to the stepwise activation of all adenosine receptors, 
including the lowaffinity A2B and A3 subtypes. Adenosine has been classified as a “retaliatory 
metabolite” as a consequence of its ability to mediate an autoregulatory loop, the function of which 
is to protect organs from injury following the initiating stressful stimuli (Newby 1984; Hasko et al., 
2004). There are different mechanisms by which adenosine receptor activation protects organs. 
First, it decreases the energy demand of the tissue, second it can augment oxygen and nutrient 
supply through vasodilation, and finally, it regulates the exuberant immune response to harmful 
external agents. As basal adenosine levels have only a marginal influence on the immune response, 
ischaemic and inflammatory conditions represent scenarios in which adenosine levels become high 
enough to have significant immunomodulatory and specifically immunosuppressive effects (Gessi 
et al., 1999). 
 
 
Adenosine inhibits lymphocyte activation through A2 receptor activation 
A body of literature concerning in vitro and in vivo studies clearly shows the beneficial role of 
adenosine as an immune modulator. Activation of T lymphocytes starts from the recognition of 
antigen by T cell antigen receptor and CD4 or CD8 coreceptors that initiates a cascade of signalling 
events resulting in cytokine secretion, cellular cytotoxicity and T cell proliferation. The 
immunosuppressive effects of adenosine on cytotoxic T lymphocyte (CTL) actions may be 
explained by activation of A2A receptors followed by sustained increases in cAMP that, in turn, 
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antagonize T cell receptor (TCR)-triggered signalling. In particular, adenosine modulates TCR-
mediated interleukin (IL)-2 production, expression of CD25 and CD69, granule exocytosis, Fas 
ligand up-regulation and cell proliferation through the interaction with A2A receptors (Huang et al., 
1997; Koshiba et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Role of adenosine receptors in the regulation of immune responses 
 
The predominant expression of A2A receptors, which has been established in functional assays using 
selective agonists and antagonists of A2A receptors, was confirmed by Northern blot studies (Huang 
et al., 1997; Koshiba et al., 1997). The role of A2A adenosine receptors in the regulation of the 
immune response has been investigated by determining the expression levels of this receptor in 
different subsets of functional lymphocytes (Koshiba et al., 1999). The levels of expression of A2A 
receptors have been found to be much higher among T than B cells. T cell subsets are distinguished 
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by the expression of TCR coreceptor molecules CD8+ and CD4+ involved in recognition of class I 
and class II major histocompatibility complex, respectively. More CD4+ than CD8+ T cells express 
A2A adenosine receptors. CD8+ T cells are mostly cytotoxic effector cells, whereas CD4+ cells have 
been implicated in T-helper cell activities. Studies of T-helper cell subsets (TH1 and TH2) reveal 
that lymphokine-producing cells are much more likely to express A2A receptors than are cells that 
do not produce lymphokines. A possible explanation was that inhibitory A2A receptors are induced 
selectively in cells that produce cytokines, as a means of limiting cytokine release (Koshiba et al., 
1999). In agreement with these results, it has been reported that activation of CD4+ lymphocytes 
induced A2A receptor mRNA expression and resulted in a dose-dependent inhibition of TCR-
mediated interferon gamma (IFN-γ) production, which is the most important effector molecule 
synthesized by Th1 cells (Lappas et al., 2005). Recently, the effect of adenosine on IL-2 receptor-
associated signalling pathways was explored in T lymphocytes by Zhang and co-workers (Zhang et 
al., 2004). IL-2 is an immunomodulatory molecule crucial for the proliferation of activated T cells, 
and its receptor consists of three subunits indicated as alpha, beta and gamma. Signalling through 
this receptor for the transduction of a proliferative signal includes Jak1, Jak3 and STAT5. Jak1 and 
Jak3 activation leads to phosphorylation of tyrosine residues on IL-2 receptors. Primed by these 
events the IL-2 complex generates two major proliferative signals. One of these signals is mediated 
by the adaptor protein Shc and activates p42/p44 MAPK and phosphatidylinositol 3-kinase (PI3K) 
signalling pathways. The second proliferative signal transduced by the IL-2 receptor complex 
involves the transcription factor STAT5 that after phosphorylation translocates to the nucleus to 
control gene expression. Adenosine, by activating A2A and A2B receptors, inhibits IL-2-dependent 
proliferation through inhibition of STAT5 phosphorylation. Because T cells play a major role in 
antitumour immunity and considering that adenosine is highly increased on the microenvironment 
of solid carcinomas, the adenosine-induced defect in IL-2-stimulated proliferative signalling would 
be expected to result in a defective T lymphocyte response in cancer patients and generally in 
impaired antitumour immunity (Figure 1). Impairment of proliferation has been recently 
 - 52 -
investigated also in anergic B lymphocytes (Minguet et al., 2005). In B cells adenosine inhibits 
activation of NF-kappa B in response to B cell antigen receptor (BCR) triggering (Fig. 1). Stimuli 
known to enhance 3′,5′-cyclic adenosine monophosphate (cAMP) are capable of selectively 
suppressing the activation both of NF-kB downstream of the BCR and Toll-like receptor 4 in 
splenic B lymphocytes. This suppression is reached by blocking phosphorylation and subsequent 
degradation of the inhibitor of NF-kappa B. This suggests that adenosinemediated signals represent 
an important step in the molecular decision process controlling inflammation versus anergic 
immune responses. In this way adenosine might affect B cell dysfunction in ADA deficiency and 
may explain defective B cell proliferation and activation found in ADA-deficient mice (Aldrich et 
al., 2003). Convincing evidence of a link between adenosine receptors and NF-kB activation comes 
also from in vivo studies performed in A2A adenosine receptor knockout (KO) mice. 
Lipopolysaccharide (LPS), given to these animals, induced a greater inflammatory response and a 
higher binding of NF-kB to nuclear DNA and consequently a higher cytokine gene transcription in 
macrophages (Lukashev et al., 2004). 
 
In vivo evidence of the immunosuppressive effects played by adenosine through 
A2A receptors  
Although it has been demonstrated that adenosine in vitro acted as an immunosuppressing agent it 
was not clear, until genetically modified mice were available, whether its effects were present also 
under pathophysiological conditions in vivo. There are many G protein-coupled receptors that 
increase cAMP levels showing immunosuppressive pharmacological effects and that have been 
considered as potential anti-inflammatory agents, e.g. catecholamines, prostaglandins, dopamine 
and histamine. However, although pharmacological evidence underlines their importance as 
potential immunosuppressive molecules, there is no real proof whether their recruitment does occur 
during physiological control of inflammation in vivo. Such evidence has been obtained for 
adenosine A2A receptors. In wildtype mice, activation of A2A receptors blocked tissue damage 
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induced by inflammation demonstrating its role in counteracting inflammation (Cronstein 1994; 
Hasko et al., 1996). More recently, the availability of A2A receptor-deficient mice in models of 
acute liver inflammation and sepsis provided the first conclusive in vivo evidence of A2A receptors 
playing a critical role in the suppression of acute inflammation. Evaluation of T cell-, macrophage- 
and cytokine-dependent tissue injury in A2A adenosine receptor-deficient mice revealed a dramatic 
increase of local tissue damage and an increase of proinflammatory cytokines such as tumour 
necrosis factor α (TNF-α), IFN-γ and IL-12 in these mice, but not in wild-type animals (Ohta et al., 
2001; Sitkovsky 2003). Moreover, low doses of inflammatory stimuli, which were not damaging in 
wild-type animals, were detrimental in terms of liver status and cytokine levels in knockout mice. 
These data furnished the first indisputable demonstration of an in vivo role played by A2A adenosine 
receptor in the regulation of inflammation and underlined a non-redundant role in the down-
regulation of inflammation in vivo. Importantly, A2A receptors seem to be essential as demonstrated 
by the failure of all other anti-inflammatory mechanisms, e.g. β-adrenergic and prostaglandin 
receptors, to overcome the lack of A2A receptors in preventing severe tissue injury. Experiments 
performed in thymocytes and T cells from heterozygous A2A receptor mice showed that there was a 
correlation between reduction of A2A receptors and reduction of cAMP response of the cells after 
activation with adenosine and suggesting the lack of A2A spare receptors in T cells and a lack of 
compensation by the A2B receptors (Armstrong et al., 2001). Also the level of apoptosis of 
thymocytes from these animals was less pronounced following A2A activation in comparison to that 
obtained in wild-type mice. The expression of other adenosine subtypes like A1, A2B or A3 did not 
compensate for the lack of A2A in lymphoid organ of deficient mice as suggested by real-time 
reverse transcription polymerase chain reaction (RT-PCR) experiments indicating again that in 
acute models of inflammation, the A2A receptors play a crucial and non-redundant role in the 
protection of tissue from damage derived by excessive inflammation (Lukashev et al., 2003). It has 
been also suggested that in non-exacerbated inflammatory conditions different anti-inflammatory 
stimuli, such as other adenosine receptor subtypes and other anti-inflammatory mediators, may act 
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in concert to reduce the extent of damage. Therefore, based on the evidences reported above, the 
treatment of a series of diseases such as sepsis, wound healing and rheumatoid arthritis, might 
improve following A2A receptor stimulation. Indeed, methotrexate (MTX), which is used for 
treatment of rheumatoid arthritis, may mediate its effects through the release of endogenous 
adenosine (Khan et al., 2002). Even though its mechanism of action remains unclear, it has been 
shown that MTX caused a dose-dependent suppression of T cell activation and adhesion molecule 
expression, and this was not due to lymphocyte apoptosis. The suppression of intercellular adhesion 
molecule (ICAM)-1 was adenosine and folate dependent, suggesting that the suppression of T cell 
activation and T cell adhesion molecule expression, rather than apoptosis, mediated in part by 
adenosine or polyglutamated MTX or both, are important mechanisms in the anti-inflammatory 
action of MTX (Johnston et al., 2005). Besides methotrexate, there is evidence that other 
therapeutic agents, such as sulfasalazine and FK-506, could exert their anti-inflammatory effects by 
promoting adenosine release (Gadangi et al., 1996; Hwang et al., 2001). 
 
Adenosine inhibits killer T cell activation via A3 and A2A stimulation: 
implications in cancer 
The ability of immune cells to recognize and eliminate tumour cells is fundamental for successful 
host defence against cancer. It has been suggested that adenosine, the concentration of which 
increases within hypoxic regions of solid tumours, may interfere with the recognition of tumour 
cells by cytolytic effector cells of the immune system (Blay et al., 1997; Merighi et al., 2003). 
Adoptive immunotherapy with lymphokine-activated killer (LAK) cells has shown some promise in 
the treatment of certain cancers that are unresponsive to conventional treatment approaches. 
However, colon adenocarcinomas tend to respond poorly to LAK therapy, possibly as a result of 
tumour-induced immunosuppression. In 1994 Hoskin and co-workers demonstrated that colon 
adenocarcinoma cells inhibited anti-CD3-activated killer cell induction through the production of a 
tumour-associated soluble factor that was distinct from transforming growth factor beta or 
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prostaglandins (Hoskin et al., 1994a,b). In the same period these authors indicated adenosine as a 
possible inhibitor of killer T cell activation in the microenvironment of solid tumours (Hoskin et al., 
1994b) and showed that 2-chloroadenosine (2CA), a stable analogue of adenosine, reduced MHC-
unrestricted killing of P815 tumour target cells by anti-CD3-activated killer (AK) lymphocytes. 
2CA exerted this effect by interfering with the recognition/adhesion phase of cytolysis. Treatment 
with dipyridamole to block cellular uptake of 2CA increased the inhibition of cytolysis, suggesting 
the involvement of a cell surface receptor. However, neither DPCPX nor DMPX, the A1 and A2 
receptor antagonists, respectively, were able to reduce the inhibitory effect of 2CA on AK 
lymphocyte function. Similarly, the nonselective A1 and A2 receptor blockers, theophylline and 8-
phenyltheophylline, had no effect on 2CA-mediated inhibition of AK cell activity. These data 
clearly demonstrated that 2CA inhibited the cytolytic activity of AK lymphocytes by interacting 
with a novel non-A1/A2 cell surface receptor (Hoskin et al., 1994c). Then, MacKenzie and co-
workers (MacKenzie et al., 1994) evaluated the adhesion of murine spleen-derived anti- CD3-
activated killer (AK) lymphocytes to syngeneic MCA-38 colon adenocarcinoma cells. Adenosine, 
in the presence of the adenosine deaminase inhibitor coformycin, reduced adhesion by up to 60%. 
The inhibitory effect of adenosine was exerted on AK cells and not on the MCA-38 targets and was 
mediated by cell surface receptors as adenosine-induced inhibition of adhesion was not abrogated 
following treatment with dipyridamole, a blocker of adenosine uptake. The agonist potency profile 
indicated that the A3 receptor subtype might be responsible for the inhibition of adhesion. The 
authors suggested that this mechanism of immunosuppression, secondary to tissue hypoxia, may be 
important in the resistance of colorectal and other solid cancers to immunotherapy. In addition, the 
same authors demonstrated that adenosine exerts a strong inhibitory effect on the induction of 
mouse cytotoxic T cells (Hoskin et a., 2002). Diminished tumouricidal activity correlated with 
reduced expression of mRNAs coding for granzyme B, perforin, Fas ligand and TNF-related 
apoptosis-inducing ligand (TRAIL) (Figure 1). IL-2 and IFN-γ synthesis by AK-T cells was also 
inhibited by adenosine. Also in this case the inhibitory effect of adenosine on AK-T cell 
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proliferation was blocked by an A3 receptor antagonist, suggesting that adenosine acts through A3 
receptors to prevent AK-T cell induction. Tumour-associated adenosine may act through the same 
mechanism to impair the development of tumour-reactive T cells in cancer patients. Therefore, the 
suppression of T killer cell function suggests that adenosine may act as a local immunosuppressant 
within the microenvironment of solid tumours. The same authors reported that adenosine partially 
inhibits the interaction of T lymphocytes with tumour cells by blocking the function of integrin 
α4β7, which is the major cell adhesion molecule involved in the adhesion of T cells to syngeneic 
MCA-38 adenocarcinoma cells (MacKenzie et al., 2002). Importantly, involvement of α4β7 has 
also been postulated in leukocyte localization in inflammatory disorders such as asthma, intestinal 
inflammation and rheumatic disorders and may be regulated by adenosine (Walsh et al., 1996; 
Michetti et al., 2000; Elewaut et al., 1998). As adenosine is known also for its anti-inflammatory 
effects in addition to its immunosuppressive actions, it is possible to hypothesize that adenosine-
mediated inhibition of adhesion through α4β7 found in T cells may be important in a variety of 
other inflammatory diseases. Tumour microenvironment can suppress the function of tumour-
infiltrating T cells. Therefore, the effect of adenosine has been investigated on the expression of 
costimulatory molecules by T cells in resting and activated conditions. One of the most important 
costimulatory molecules present on the T cells’ surface are CD2 and CD28 acting in concert to 
achieve optimal costimulation of T lymphocytes during interaction with antigen-presenting cells. It 
has been demonstrated that adenosine interfered with activation-induced expression of the 
costimulatory molecules CD2 and CD28 and that their up-regulation was IL-2 dependent. This 
effect could not be attributed to cyclic AMP (cAMP) accumulation resulting from the stimulation of 
adenylyl cyclase-coupled adenosine receptors, even though cAMP at concentrations much higher 
than those generated following adenosine stimulation was inhibitory for both CD2 and CD28 
expression. Therefore, it has been proposed that adenosine interferes with IL-2-dependent T cell 
expression of costimulatory molecules via a mechanism that does not involve the accumulation of 
intracellular cAMP and through a cell surface receptor that is coupled to signalling pathways 
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different from those involving adenylyl cyclase activity, possibly the A3 subtype (Butler et al., 
2003). However, the relevance of adenosine-mediated pathways in tumour-infiltrating T cells, 
considering the expression on T cells of adenosine deaminase in association with CD26 (dipeptidyl 
aminopeptidase), remains to be elucidated (Dong et al., 1996). CD26 is a multifunctional type II 
cell surface glycoprotein widely expressed on T, B and natural killer (NK) cells. One of its 
functions is that of an adenosine deaminase binding site. Binding of ADA to CD26 is capable of 
reducing the local concentration of adenosine and has an enzymatic role in protecting T cells from 
an adenosine-mediated inhibition of proliferation [Dong et al., 1996; Gorrell et al., 2001). Indeed, it 
has been reported that adenosine deaminase activity is significantly lower in the peripheral 
lymphocytes of cancer patients, suggesting increased susceptibility of T cells to adenosine-mediated 
inhibition within the tumour microenvironment (Dasmahapatra et al., 1986). Moreover, cytotoxic T 
cells show very low levels of adenosine deaminase activity, leaving us to hypothesize that cytotoxic 
cells would be quite sensitive to the immune inhibitory effect of adenosine accumulated within 
tumours. In this regard, it is relevant to underline that the presence of the A3 adenosine receptor has 
been demonstrated in Jurkat cells, a human leukaemic cell line, where its level is very high, and in 
human lymphocytes in which an up-regulation occurs after T cell activation (Gessi et al., 2001, 
2004). In addition to the A3 receptors, antigen activation has been shown to alter the expression of 
other adenosine subtypes. For example it has been reported that A2B receptors are also up-regulated 
by phytohemagglutinin (PHA) and/or anti-CD3 in both CD4+ and CD8+ cells (Mirabet et al., 
1999), and as for A2A subtypes there are contrasting reports suggesting both that the activation 
process increases their expression predominantly in CD8+ and/or CD4+ T cells (Koshiba et al., 
1999; Lappas et al., 2005). These data suggest that adenosine may stepwise recruit different 
adenosine receptors following antigen activation. In human lymphocytes, e.g. A2A and A2B 
receptors are coexpressed, leading to synergy in cAMP production (Gessi et al., 2005); in addition, 
adenosine may mediate different signals if each of these receptors is linked to different effector 
molecules, as is the case of the A3 subtype. In contrast to the immunosuppressive role of adenosine 
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in the environment of solid tumours, recent findings from in vivo studies of Fishmans’ group report 
a stimulatory effect of A3 agonists in the synthesis of IL-12 that is dependent from inhibition of 
cAMP levels and protein kinase A expression. This cytokine is a potent stimulatory agent of NK 
cells and is a cytotoxic factor that exerts a potent antitumour effect in vivo. It induces IFN-+ 
production by activated T and NK cells and augments cytotoxic activity of these cells via perforin, 
Fas and TRAIL-dependent mechanisms. Therefore, it enhances NK cell activity and probably NK 
cell-mediated destruction of tumour cells (Harish et al., 2003). This antitumour effect played in 
immune cells is in line with other findings of the same group demonstrating a direct inhibitory 
action of A3 receptor activation on tumour cell growth (Fishman et al., 2001). However, in general, 
it has to be remarked that contrasting results obtained from pharmacological studies may be 
explained by the limitations due to the poor selectivity of agonists and antagonists for adenosine 
receptors. Recent data obtained from studies using adenosine receptor KO mice examined the 
capability of adenosine and its analogues to inhibit the ability of lymphokine-activated killer cells 
(LAK) to kill tumour cells. This work demonstrated that adenosine and adenosine A2A ligands 
suppress the cytotoxicity of LAK cells in parallel with their ability to increase cAMP levels. These 
effects were produced by interfering with both perforin-mediated and Fas ligand-mediated killing 
pathways. Studies with LAK cells generated from A1 and A3 adenosine receptor KO mice indicated 
the lack of any involvement of these adenosine subtypes in the inhibitory effect exerted by 
adenosine, whereas LAK cells obtained from A2 adenosine receptor KO mice were resistant to the 
inhibitory effect of this nucleoside. Only very high concentrations of the nonselective agonists 
NECA or CADO produced mild inhibition of LAK cytotoxicity that were possibly induced through 
A2B activation, suggesting a predominant role of A2A subtype in inhibition of LAK cell toxicity 
(Raskovalova et al., 2005). Therefore, adenosine has been indicated as an important intra-tumour 
factor that inhibits the effector function of NK and T cells and protects tumours from immune 
destruction. Being that these effects are mediated by A2A receptors, the authors suggest the 
introduction of A2A antagonists to increase the efficacy of immunotherapy. 
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Conclusion and perspectives 
The evidences summarized in this review indicate that adenosine through the interaction with A2 
and A3 receptors plays a crucial role in the regulation of immune cells. The most important 
therapeutic implication arising from the data summarized above is that A2A receptors, proposed as 
“natural” brakes of inflammation, appear to represent a promising pharmacological target to treat a 
wide variety of diseases characterized by a strong immunoinflammatory component. On the other 
hand, it may be advantageous in some circumstances to enhance certain aspects of inflammation in 
order to eliminate the causative agent, as in the case of cancer. In fact, it has to be remarked that 
tumour defence mechanisms are akin to inflammatory processes. Solid tumours, due to their 
abnormal vasculature, are often hypoxic and show increased levels of adenosine that may be an 
important mediator of tumour-associated immunosuppression. It is likely that killer T cells that may 
be recruited against cancer cells fail to act in an effective manner due to the high level of adenosine 
in the tumour microenvironment. Because several of these immunosuppressive functions have been 
attributed to the stimulation of A3 and A2A receptors, expressed on the surface of T cells, adenosine 
antagonists of these subtypes may be potentially useful in the immunotherapy of cancer. 
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A3 adenosine receptor regulation of cells of the 
immune system and modulation of inflammation 
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Introduction 
The interest in the elucidation of A3 adenosine receptor involvement in inflammation is evident from 
the large amount of experimental work carried out in peripheral blood cells of the immune system 
and in a variety of inflammatory conditions. Following a detailed analysis of the literature the A3 
adenosine receptor subtype appears to play a complex role as both pro and anti-inflammatory effects 
have been demonstrated depending not only on the cell types investigated but also on the model of 
inflammation used and the species considered (Gessi et al., 2008). This chapter will discuss 
developments in our understanding of the role of adenosine A3 receptor activation in the function of 
the different types of cells of the immune system including neutrophils, eosinophils, lymphocytes, 
monocytes, macrophages and dendritic cells. 
 
A3 adenosine receptor effects on neutrophil function 
Neutrophils represent a larger percentage of circulating leukocytes than any other cell type. They are 
the first white blood cells to arrive at an injured or infected site. Neutrophils arise in the bone 
marrow and then must traverse the vasculature to arrive at the sites of injury. They leave the 
circulation at the level of the postcapillary venules following specific interaction with endothelium. 
Once in the extravascular space, neutrophils follow a gradient set up by chemoattractants, such as 
activated complement components, cytokines, lipids or bacterial products by means of specific cell 
surface receptors. Although the primary role of the neutrophil is to rid the body of injurious 
organisms and clean up the debris after tissue injury, the extracellular release of any of the contents 
of the phagolysosome or the generation of toxic oxygen metabolites into the extracellular space can 
lead to destruction of normal, uninjured cells surrounding the infected site. It is the destruction of the 
surrounding tissue by overactive neutrophils  that adds so greatly to tissue destruction in the setting 
of reperfusion injury. Adenosine, acting through its cell surface receptors, is a potent regulator of 
neutrophil function. 
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The first report implicating a role for A3 receptors in human neutrophils came in 1997 following 
investigations into the effect of adenosine and its more selective analogues on neutrophil 
degranulation in human whole blood (Bouma et al., 1997). Adenosine inhibited concentration-
dependently the LPS- and TNF-alpha-induced release of the azurophilic granule proteins with an 
IC50 in the µmolar range. The inhibitory effects of adenosine were partially blocked by the A2 
receptor antagonist 3,7-dimethyl-1-propargylxanthine, the A1/A2 antagonist 8(p-
sulfophenyl)theophyline, and the A1/A3 antagonist xanthine amine congener, but not by the A1 
antagonist 1,3-dipropyl-8-cyclopentylxanthine. The highly selective A3 agonist N6-(3-iodobenzyl)-
adenosine-5'-N-methyluronamide and the nonselective agonist 2-chloroadenosine reduced 
degranulation more potently than the A1 agonist N6-cyclopentyladenosine. The inhibitory effects of 
N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide and 2-chloroadenosine were strongly reversed 
by xanthine amine congener, but were not affected by 8(p-sulfophenyl)theophyline. These data 
suggest that adenosine acted via A2 as well as A3 receptors to inhibit neutrophil degranulation. 
However, activation of A3 receptors in canine neutrophils did not attenuate superoxide anion 
production but reduced platelet-activating factor-stimulated neutrophil adherence to coronary 
endothelium suggesting that it might be a novel target for treatment of myocardial ischemia and 
reperfusion (Jordan et al., 1999). 
Subsequent binding and functional studies showed that human neutrophils expressed A3 receptors 
which were coupled to the inhibition of adenylyl cyclase and calcium signalling (Gessi et al., 2002). 
However in the case of calcium the high micromolar doses of the A3 agonist 2-chloro-N6-(3-
iodobenzyl)adenosine-5'-N-methylcarboxamide (Cl-IB-MECA) and the A3 antagonist 5-N-(4-
methoxyphenyl-carbamoyl)amino-8-propyl-2(2furyl)-pyrazolo-[4,3e]-1,2,4-triazolo [1,5-c] 
pyrimidine (MRE 3008F20) needed to stimulate or block Ca2+ mobilization respectively, were not 
completely consistent with the involvement of an A3 receptor. Similar effects of Cl-IB-MECA in 
mobilizing Ca2+ have been found in several cell systems a finding that is difficult to reconcile with 
the high affinity of this selective A3 agonist in binding and cAMP inhibition assays (Kohno et al., 
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1996a, b; Jacobson, 1998; Reeves et al., 2000; Reshkin et al., 2000; Shneyvays et al., 2000; Gessi et 
al., 2001; Suh et al., 2001; Merighi et al., 2001). The reason why high, nonselective doses of Cl-IB-
MECA are needed to stimulate Ca2+ mobilization remains unknown. A contribution of other 
mechanisms other than A3 receptor stimulation cannot be excluded. Importantly, for the first time it 
was suggested that both A3 and A2A receptors contribute to the inhibition of oxidative burst, an 
indication of anti-inflammatory activity (Gessi et al., 2002). Using this readout, alterations of A3 
adenosine receptors in human neutrophils exposed to low frequency, low energy pulsing 
electromagnetic fields (PEMFs) has been reported. There is considerable interest in the use of 
PEMFs in clinical practice since the date correlate well with inflammatory conditions. Saturation 
experiments after treatment with PEMFs revealed that the A3 receptor density in human neutrophils 
was increased. Consistent with this in functional assays Cl-IB-MECA and N6-(3-
iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) were able to inhibit cyclic AMP 
accumulation and their potencies were increased after exposure to PEMFs. These results indicated 
that in human neutrophils treated with PEMFs there are significant alterations in the A3 adenosine 
receptor density and functionality (Varani et al., 2003). The upregulation cannot be ascribed to the 
synthesis of new receptors since the duration of PEMF treatment was too short. The upregulation of 
A3 adenosine receptors is most likely due to a translocation of this receptor subtype to the membrane 
surface. It is of interest that PEMFs treatment also modified the binding parameters of the A2A 
adenosine receptors but not those of α2, β2 adrenergic and µ, k opioid receptors suggesting a 
relationship between adenosine receptor-mediated anti-inflammatory effects and PEMF exposure 
(Varani et al., 2002). 
An up-regulation of the A3 adenosine receptor has also been observed in neutrophils obtained from 
patients with colorectal cancer in comparison with healthy subjects. This overexpression was found 
to reflect at peripheral level the same up-regulation found in the tumoral tissue from the colon in 
comparison to healthy mucosa, suggesting that peripheral A3 adenosine receptors in neutrophils 
might represent potential marker for revealing colorectal cancer (Gessi et al., 2004a). It was also 
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found that in a small cohort of subjects A3 receptor expression of circulating blood cells normalizes 
after surgical treatment, consistent with the negative results of follow-up evaluation with 
carcinoembryonic antigen (CEA), computed tomography scan, and colonoscopy. Hence, the 
improved health of patients after surgical resection seems to be associated with restoration of a 
normal adenosinergic system, at least in terms of A3 receptor expression. These findings might be 
used for clinical applications. In particular, examination of neutrophil A3 expression (for example, in 
addition to CEA determination) could play a role in the screening of high-risk individuals or in the 
follow-up of patients after surgical resection. 
Recently Chen et al. reported that migrating human neutrophils secrete ATP at the leading edge, 
which signals via P2Y2 receptors to amplify chemoattractant signals (Chen et al., 2006a). 
Neutrophils rapidly hydrolyze released ATP to adenosine which then acts via A3 receptors, which 
are recruited to the leading edge, to promote cell migration. In resting cells, A3 receptors appear to 
be located primarily in intracellular compartments associated with granules (Chen et al., 2006a). 
Upon cell stimulation with chemoattractant, A3 receptors are rapidly mobilized at the leading edge to 
promote chemotaxis. Thus, ATP release and autocrine feedback through P2Y2 and A3 receptors 
provides signal amplification and controls gradient sensing and migration of neutrophils. 
Interestingly, chemotaxis of neutrophils obtained from A3 receptor knockout (KO) animals is 
inhibited.  In contrast, A2A receptors are uniformly distributed across the cell surface and cell 
polarization does not seem to change this distribution pattern (Chen et al., 2006a). This suggests that 
the inhibitory A2A receptors may function to globally suppress pseudopod formation across the 
entire cell surface of neutrophils, except at the leading edge, where A3 adenosine receptor counteract 
the suppressive action of A2A receptors (Chen et al., 2006a; Linden, 2006; Junger, 2008). However, 
these findings were questioned recently by Hoeven et al. (2008) who demonstrated that A3 
adenosine receptor activation is responsible for inhibition of superoxide production and chemotaxis 
of mouse bone marrow neutrophils, suggesting that the A3 receptor may contribute to the anti-
inflammatory actions of adenosine. Although there are many differences between this study and the 
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earlier work, including the species difference (mouse vs human), the pharmacological agents used to 
stimulate the A3 adenosine receptor (CP-532,903 versus IB-MECA), the methods used to 
isolate/culture murine neutrophils, the stimulation protocols (including the time and duration of 
pretreatment of cells with agonists), and the state of cell priming, a definite explanation for the 
differences in results obtained in these studies remains unclear.  
Consistent with a pro-inflammatory role of A3 adenosine receptors in human neutrophils it has been 
demonstrated that A3 receptors together with P2Y subtypes mediate neutrophil elastase release 
induced by hypertonic saline (Chen et al., 2006b). Hypertonic saline holds promise as a novel 
resuscitation fluid for the treatment of trauma patients because it inhibits polymorphonuclear 
neutrophil activation and thereby prevents host tissue damage and associated post-trauma 
complications. However, under certain conditions of cell activation, hypertonic saline can increase 
neutrophil degranulation, which could exacerbate tissue damage in trauma victim (Chen et al., 
2006b). The cellular mechanism by which hypertonic saline increases degranulation involves 
elastase release and ERK and p38 MAPK activation when hypertonic saline is added after 
submaximal activation of neutrophils with formyl peptide (fMLP) or phorbol ester (PMA). Agonists 
of P2 nucleotide and A3 adenosine receptors mimicked these enhancing effects of hypertonic saline, 
whereas antagonists of A3 receptors or removal of extracellular ATP with apyrase diminished the 
response to hypertonic saline suggesting that hypertonic saline upregulates degranulation via ATP 
release and positive feedback through P2 and A3 receptors. It has been hypothesized that these 
feedback mechanisms can serve as potential pharmacological targets to fine-tune the clinical 
effectiveness of hypertonic saline resuscitation (Chen et al., 2006b). In this context, it has been 
shown that A3 receptor activation may diminish the efficacy of hypertonic saline in a mouse model 
of acute lung injury after sepsis (Inoue et al., 2008a). Acute lung injury in wild-type mice treated 
with hypertonic saline 60 min after sepsis induction, through cecal ligation and puncture (CLP), was 
significantly greater than in wild-type mice pretreated for 5 and 15 min with hypertonic saline. 
Parallel experiments aimed at evaluating the expression of A3 receptors in human neutrophils treated 
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with hypertonic saline either 10 min before or after stimulation with formyl methionylleucyl-
phenylalanine (fMLP) reveal that in the first condition A3 receptor expression was reduced whilst in 
the second one it was markedly increased. These findings show that the opposing effects of 
hypertonic saline in vivo correlate with differences in the cell surface expression of A3 receptors, 
suggesting that the enhancing effects of hypertonic saline are a result of increased A3 receptor 
expression of stimulated neutrophils. The aggravating effect of delayed hypertonic saline treatment 
was absent in A3 receptor knockout (KO) mice. Similarly, mortality in wild-type mice with delayed 
hypertonic saline treatment was significantly higher than in animals treated with hypertonic saline 
before CLP. Mortality in A3 receptor KO mice remained at only 50% regardless of timing of 
hypertonic saline administration. These findings suggest that A3 antagonists could improve the 
efficacy of hypertonic saline resuscitation by reducing side effects in patients whose 
polymorphonuclear neutrophils are activated before hypertonic saline treatment. The role of A3 and 
P2Y2 receptors in neutrophil sequestration in the lungs in a mouse model of sepsis has also been 
demonstrated (Inoue et al., 2008b). Sepsis was induced by CLP using wild type mice, homozygous 
A3 receptor KO mice, and P2Y2 receptor KO mice. The data suggest that A3 and P2Y2 receptors are 
involved in the influx of neutrophils into the lungs after sepsis. Neutrophil sequestration in the lungs 
reached a maximum 2 h after CLP and remained significantly higher in wild type mice compared 
with A3 KO and P2Y2 KO mice. Survival after 24 h was significantly lower in WT mice than in A3 
KO or P2Y2 KO mice. Thus, pharmaceutical approaches that target these receptors might be useful 
to control acute lung tissue injury in sepsis.  
It has been recognized that the inflammatory response to infection depends on the coordinated 
interaction of the adenine nucleotides, ATP, ADP and adenosine released by damaged tissue 
(Linden, 2006). Therefore the contribution of A3 receptors expressed in neutrophils, must be in 
concert with the other purinergic receptors to allow neutrophil adhesion, extravasation and 
chemotaxis. Neutrophils express predominantly A2A and A3 receptors which have opposite effects 
on these cells. In this chapter we have described how neutrophils following gradients of ATP and 
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adenosine initiate and increase the speed of chemotaxis via P2Y and A3 receptors, respectively and 
that the A2A may amplify gradient signals by inhibiting chemotaxis at membrane region distant from 
the leading edge where the A3 receptor predominates and increases chemotaxis. This seems possible 
given that the affinity of adenosine for the A2A receptor is several orders of magnitude higher than 
its affinity for the A3 receptors. Thus, differences in external adenosine concentrations in the 
environment surrounding migrating neutrophils may contribute to the regulation of chemotaxis 
(Chen et al., 2006a). A coordinated activity of A2A and A3 receptors has also been found with respect 
to degranulation and superoxide anion production in human neutrophils where both receptors 
cooperate to fine-tune the inflammatory response (Bouma et al., 1997; Gessi et al., 2002). However, 
it is important that the inhibitory effect exerted by A2A and A2B receptors on chemotaxis and 
adhesion to endothelial cells, respectively can overcome the stimulatory effect exerted by A3 when 
excessive influx of neutrophils damages host tissues (Zhang et al., 2006). After activation of A3 
receptors opposite effects on inflammation have been reported depending essentially on the response 
considered, the experimental conditions and the species used. It is relevant to underline that by 
comparing the studies performed in human neutrophils both anti and proinflammatory effects have 
been demonstrated (Figure 1). Therefore caution should be used before proposing A3 agonists as 
anti or proinflammatory agents until a more definite role of this receptor has been defined. 
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Figure 1: Effects of A3 adenosine receptors in neutrophils 
 
 
 
ANTI-INFLAMMATION PRO-INFLAMMATION 
Degranulation 
(Bouma et al. 1997) 
Chemotaxis 
(Chen et al. 2006a) 
Oxidative Burst 
(Gessi et al. 2002; Van Der Hoeven et al. 2008) 
Degranulation: elastase     
release, after hypertonic 
saline treatment 
(Chen et al. 2006b) 
Chemotaxis 
(Van Der Hoeven et al. 2008) 
Human Neutrophils 
 - 73 -
A3 adenosine receptor effects on eosinophil function 
Eosinophils are one of the immune system components responsible for combating infection. Along 
with mast cells, they also control mechanisms associated with allergy and asthma. Eosinophils 
develop and mature in the bone marrow. They differentiate from myeloid precursor cells in response 
to the cytokines interleukin 3 (IL-3), interleukin 5 (IL-5), and granulocyte macrophage colony-
stimulating factor (GM-CSF). Eosinophils produce and store many secondary granule proteins prior 
to their exit from the bone marrow. After maturation, eosinophils circulate in blood and migrate to 
inflammatory sites in tissues, in response to chemokines such as CCL11 (eotaxin-1), CCL24 
(eotaxin-2), CCL5 (RANTES), and leukotriene B4 (LTB4). At these infectious sites, eosinophils are 
activated by Type 2 cytokines released from a specific subset of helper T cells (Th2); thus IL-5, GM-
CSF, and IL-3 are important for eosinophil activation as well as maturation. Following activation, 
eosinophils release the contents of small granules within the cellular cytoplasm, which contain many 
chemical mediators, such as histamine and proteins such as eosinophil peroxidase, RNase, DNases, 
lipase, plasminogen, and major basic protein that are toxic to both parasite and host tissues (Gleich 
and Adolphson, 1986). 
A3 receptors are present on human eosinophils and couple to signalling pathways that lead to cell 
activation ( Kohno et al., 1996a; Reeves et al., 2000).  Despite this it has not proven easy to 
demonstrate the functional consequences of activation of these sites (Reeves et al., 2000).  
Nevertheless, the chronic inflammation in asthma is characterised by extensive infiltration of the 
airways by activated eosinophils  (Holgate, 1999; Pearlman, 1999) and it remains possible that the 
elevated adenosine concentrations associated with asthma  would contribute to eosinophil activation 
through stimulation of A3 receptors.  In addition, it has been speculated that activation of A3 
receptors may protect eosinophils from apoptosis (Gao et al., 2001).  Thus, blockade of A3 receptors 
may reduce the numbers of eosinophils and their activation thereby reducing the pro-inflammatory 
burden in the lung.  Consistent with this, following 6 weeks treatment of mild asthmatics with 
 - 74 -
theophylline there was a significant reduction in the number of activated eosinophils beneath the 
epithelial basement membrane (Sullivan et al., 1994).  Significantly, the average blood levels in this 
study (37 µM) were within the range of the affinity of theophylline for the human A3 receptor.  
Moreover, it has been reported that activation of A3 receptors mediates inhibition of eosinophil 
chemotaxis (Knight et al., 1997).  The authors argue that since adenosine levels are highest at the 
site of inflammation, A3 receptor activation would be pro-inflammatory by inhibiting eosinophil 
migration away from the sites of inflammation.  Clearly,  however, inhibition of chemotaxis could 
be pro- or anti-inflammatory. In line with a pro-inflammatory role, a high expression of A3 receptor 
transcripts has been found in eosinophilic infiltrates of the lungs of patients with asthma and chronic 
obstructive pulmonary disease (COPD) (Walker et al., 1997). Interestingly, similar findings were 
seen in the lungs of adenosine deaminase deficient (ADA-/-) mice that showed adenosine-mediated 
lung disease. Treatment of ADA-/- mice with MRS 1523, a selective A3 receptor antagonist, 
prevented airway eosinophilia and mucus production. Similar results were obtained in the lungs of 
ADA/ A3 receptor double KO mice, suggesting that A3 receptor signalling plays an important role in 
regulating chronic lung disease and that A3 receptor antagonism may be useful for reducing 
eosinophilia (Young et al., 2004). However these results contrast with those from experiments 
performed in human eosinophils ex vivo, where chemotaxis, degranulation and superoxide anion 
production were reduced by A3 receptor activation (Knight et al., 1997; Walker et al., 1997; 
Ezeamuzie and Philips, 1999). This discrepancy was later attributed to the ex vivo nature of the 
chemotaxis experiments and implied that diminished airway eosinophilia seen in the lungs of ADA-/- 
mice following disruption of A3 receptor is not a direct effect on the eosinophils but be due to the 
modulation of key regulatory molecules from other cells that express A3 receptors and that affect 
eosinophil migration (Young et al., 2004). For example A3 receptors are expressed on murine mast 
cells, airway macrophages and epithelial cells, all of which might affect eosinophil migration. 
However levels of key regulatory cytokines such as IL-5 and IL-13, or chemokines including 
eotaxin I, thymus- and activation-regulated chemokine (TARC) and monocyte chemotactic protein-3 
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(MCP3) were not affected by A3 receptor deletion in ADA-/- mice, pointing perhaps to the 
involvement of A3 receptor in the regulation of other key modulators of eosinophil migration such as 
cell adhesion molecules, extracellular matrix elements and proteases (Young et al., 2004). In 
contrast to a pro-inflammatory role of the A3 subtype implied by the work of Young and colleagues 
cited above, the involvement of the A3 adenosine receptor in a bleomycin model of pulmonary 
inflammation and fibrosis seems to indicate an anti-inflammatory effect (Morschl et al., 2008). 
Analysis of A3 adenosine receptor KO mice revealed enhanced pulmonary inflammation including 
an increase in eosinophils and a selective up-regulation of eosinophil related chemokines and 
cytokines in the lungs of A3 adenosine receptor KO mice exposed to bleomycin. This increase in 
eosinophil numbers was accompanied by a decrease in the eosinophil peroxidase activity in lavage 
fluid from A3 adenosine receptor KO mice exposed to bleomycin, an observation suggesting the A3 
adenosine receptor is necessary for eosinophil degranulation in this model. Together these results 
suggest that the A3 adenosine receptor mediates anti-inflammatory functions in the bleomycin 
model, and is also involved in regulating the production of mediators that can impact fibrosis 
(Morschl et al., 2008). The effects obtained in human eosinophils after A3 receptor activation 
including inhibition of chemotaxis, degranulation, oxidative burst and the effects obtained from in 
vivo models of lung disease such as eosinophilia and mucus production are summarized in Figure 2. 
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Figure 2: Effects of A3 adenosine receptors in eosinophils 
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A3 adenosine receptor effects on lymphocyte function 
The ability of immune cells to fight tumor cells is fundamental for successful host defence 
against cancer. Adenosine, whose concentration increases within hypoxic regions of solid 
tumors, may interfere with the recognition of tumor cells by cytolytic effector cells of the 
immune system (Blay et al., 1997; Merighi et al., 2003). Adoptive immunotherapy with 
lymphokine-activated killer (LAK) cells has shown some promise in the treatment of certain 
cancers that are unresponsive to conventional treatment approaches. However, colon 
adenocarcinomas tend to respond poorly to LAK therapy, possibly as a result of tumor-induced 
immunosuppression. It has been demonstrated that colon adenocarcinoma cells inhibited anti-
CD3-activated killer cell induction through the production of a tumor-associated soluble factor 
that was distinct from transforming growth factor beta or prostaglandins (Hoskin et al., 1994a). 
As a result, adenosine was suggested as a possible inhibitor of killer T-cell activation in the 
microenvironment of solid tumours (Hoskin et al., 1994b; Hoskin et al., 1994c). Indeed, 
evaluating the adhesion of murine spleen-derived anti-CD3-activated killer (AK) lymphocytes 
to syngeneic MCA-38 colon adenocarcinoma cells it was found that adenosine reduced 
adhesion by up to 60% (MacKenzie et al., 1994). The inhibitory effect of adenosine was exerted 
on AK cells and not on the MCA-38 targets and the agonist potency profile indicated that the 
A3 receptor subtype might be responsible for the inhibition of adhesion. The authors suggested 
that this mechanism of immunosuppression, secondary to tissue hypoxia, may be important in 
the resistance of colorectal and other solid cancers to immunotherapy. In addition the same 
authors demonstrated that adenosine plays a strong inhibitory effect on the induction of mouse 
cytotoxic T cells (Hoskin et al., 2002). Diminished tumoricidal activity correlated with reduced 
expression of mRNAs coding for granzyme B, perforin, Fas ligand and TNF-related apoptosis-
inducing ligand (TRAIL). Interleukin-2 (IL-2) and interferon-γ (IFN-γ) synthesis by AK-T cells 
was also inhibited by adenosine. The inhibitory effect of adenosine on AK-T cell proliferation 
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was also blocked by an A3 receptor antagonist suggesting that adenosine acts through A3 
receptors to prevent AK-T cell induction. Tumor-associated adenosine may act through the 
same mechanism to impair the development of tumor-reactive T cells in cancer patients. 
Therefore the suppression of T-killer cell function suggests that adenosine may act as a local 
immunosuppressant within the microenvironment of solid tumors. Subsequently it was reported 
that adenosine partially inhibits the interaction of T lymphocytes with tumor cells by blocking 
the function of integrin α4β7 which is the major cell adhesion molecule involved in the 
adhesion of T cells to syngeneic MCA-38 adenocarcinoma cells (MacKenzie et al., 2002). The 
effect of adenosine has been investigated on the expression of costimulatory molecules by T 
cells in resting and activated conditions. The most important costimulatory molecules present 
on the T cells surface are CD2 and CD28 acting in concert to achieve optimal costimulation of 
T lymphocytes during interaction with antigen presenting cells. It has also been demonstrated 
that adenosine interferes with activation-induced expression of the co-stimulatory molecules 
CD2 and CD28 by an IL-2 dependent mechanism but not involving the accumulation of 
intracellular cAMP and possibly by activating the A3 subtype (Butler et al., 2003). Subsequently 
the inhibitory effect mediated by adenosine on the ability of LAK cells to kill tumor cells was 
attributed essentially to the cAMP-elevating A2A receptor whilst no evidence of the involvement 
of cAMP inhibitory A1 or A3 subtypes in the regulation of the cytotoxic activity of LAK cells 
was found (Raskovalova et al., 2005). Indeed, it has been suggested that hypoxic cancerous 
tissues may be protected by the same hypoxia→adenosine→A2A receptor pathway that was 
recently shown to be critical and nonredundant in preventing excessive damage of normal 
tissues by overactive immune cells in vivo (Ohta et al., 2001). 
In contrast to the immunosuppressive role of adenosine in the environment of solid tumors, it 
has been reported that A3 receptor activation stimulates the proliferation of murine bone marrow 
cells in vitro. This effect was induced through the G-CSF production by human peripheral 
blood mononuclear cells (PBMC) mediated by adenosine. The finding was confirmed in vivo 
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experiments, which revealed an increase in leukocyte and neutrophil numbers when adenosine 
was administered before chemotherapy (Fishman et al., 2000). The molecular mechanisms 
underlying G-CSF production included the upregulation of  the PI3K, PKB/Akt and NF-kB 
pathways (Bar-Yehuda et al., 2002). In addition, it has been observed that Cl-IB-MECA 
increases the activity of NK cells in naïve and tumor bearing mice through the induction of IL-
12; this effect was dependent on inhibition of cAMP levels and PKA expression. IL-12 is a 
potent stimulant of NK cells and is a cytotoxic factor that exerts a potent anti-tumor effect in 
vivo. It induces IFN-γ production by activated T and NK cells and augments cytotoxic activity 
of these cells via perforin, Fas and Trail-dependent mechanisms. Therefore, A3 receptor 
activation enhances NK cell activity and probably NK cell-mediated destruction of tumor cells 
(Harish et al., 2003). The expression of A3 receptor was also investigated in resting and 
activated lymphocytes (Gessi et al., 2004b). Activated human lymphocytes undergo a rapid 
induction of both transcript and protein of A3 receptors. The kinetics of this up-regulation 
revealed that even at earlier time points, the increase was present only in CD4+ cells, whereas it 
was not changed in CD8+ cells. Therefore, it is possible that in humans, as in mice (Hoskin et 
al., 2002), A3 receptors play an immunosuppressive role in CD8+ T cells, but their up-regulation 
in CD4+ cells strongly suggests that they might also be implicated in T helper cell activities. 
One method of increasing the number of A3 receptors on the cell membrane is to increase the 
accumulation of mRNA encoding the A3 subtypes. As evaluated by means of real-time RT-PCR 
experiments, activation of T cells with PHA rapidly increased the level of A3 message in the 
CD4+ subset, but not in the CD8+ cells. This increase in A3 receptor mRNA, which could occur 
as a result of an increase in transcription and/or an increase in mRNA stability, is likely to be 
responsible for the increased synthesis of receptor proteins as detected by means of binding and 
Western blot studies. The rapid up-regulation of A3 receptors functionally coupled to adenylyl 
cyclase in activated T cells may indicate another potential example of biological significance for 
adenosine-mediated responses in T cells.  
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An overexpression of A3 receptors has also been detected in lymphocytes of patients with 
colorectal cancer. Interestingly, the existence of A3 receptors was previously demonstrated on 
Jurkat cells, a human leukemic cell line, where they were associated with inhibition of adenylyl 
cyclase activity and calcium modulation (Gessi et al., 2001). Blood lymphocytes obtained from 
30 colorectal cancer patients showed a >3-fold overexpression of A3 receptors compared with 
blood cells from healthy donors, in line with the data found in tissues. No association was found 
with stage of the disease, tumor site, patient age, or gender. Even though the mechanism of this 
up-regulation are not known it is interesting that binding data from tissues, as in circulating 
blood cells, discriminate between small-sized adenomas and cancer, suggesting that A3 receptor 
may be a requirement for colorectal tumor progression. These receptors may represent, like 
those in neutrophils, tumoral markers due to their higher expression in comparison to that 
observed in healthy subjects. This suggests that peripheral blood cells mirror at the peripheral 
level the higher levels of the A3 receptor found in colorectal cancer. However the selectivity of 
the A3 receptor as a tumoral marker may be of only limited value because a similar 
phenomenon has been confirmed in patients with rheumatoid arthritis. Thus the A3 receptor was 
overexpressed in PBMC of patients with rheumatoid arthritis compared to healthy subjects and 
was directly correlated to an increase in NF-kB in the same cells (Madi et al., 2007). Similar 
data were found in phytohemagglutinin and lipopolysaccharide-stimulated PBMC from healthy 
subjects suggesting that receptor upregulation is induced by inflammatory cytokines controlling 
the expression of the A3 adenosine receptor transcription factor NF-kB (Madi et al., 2007). It 
seems that the A3 adenosine subtype found in PBMC obtained from peripheral blood may not 
represent a specific tumoral marker but more generally a marker for inflammation.  
In conclusion, it is well established that extracellular adenosine has the potential to be an 
important inhibitor of tumor cell destruction by NK and LAK cells within the 
microenvironment of solid tumors by signaling primarily through A2A and A3 adenosine 
receptors on the surface of T cells (Hoskin et al., 2008). However after the demonstration that 
 - 81 -
genetic deletion of immunosuppressive A2A and A2B receptors or their pharmacological 
inactivation can prevent the inhibition of anti-tumor T cells by the hypoxic tumor and facilitate 
full tumor rejection, several reviews focused on the relevance of A2A and in minor part of A2B 
adenosine subtypes to improve the effectiveness of immune-based cancer therapies (Ohta et al., 
2006; Lukashev et al., 2007; Sitkovsky et al., 2008a, b). In contrast to the well described 
mechanisms by which A2A adenosine receptor signaling blocks T cell activation and effector 
function, little is known about the mechanism of A3 adenosine receptor-mediated T cell 
inhibition. Moreover, while the importance of A2A adenosine receptor signaling in adenosine-
mediated suppression of T cell responses has been confirmed using A2A adenosine receptor-
deficient mice (Lukashev et al., 2003), similar confirmatory studies have not yet been 
performed with A3 adenosine receptor deficient mice. Additional studies need to be performed 
in human lymphocytes as almost all the functional effects attributed to A3 receptor activation 
are derived from studies carried out in mice species (Figure 3). The identification of adenosine 
receptor subtypes and/or signal transduction pathways through which adenosine exerts its 
inhibitory effects on cell-mediated anti-tumor immune responses may allow for the 
development of novel “anti-adenosinergic” approaches that increase the effectiveness of 
therapeutic cancer vaccines and other immune-based cancer therapies. 
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Figure 3: Effects of A3 adenosine receptors in lymphocytes 
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A3 adenosine receptor effects on monocyte-macrophage function 
In vivo and in vitro studies in animal systems led to the concept of the mononuclear-phagocyte 
system as a cell system involved in host defenses, phagocytosis, and antigen presentation and 
processing (Douglas, 1999). Following Metchnikoff's development of phagocyte theory, Wright 
described opsonins as factors in serum that facilitated phagocytosis. Aschoff defined the 
reticuloendothelial system as a cellular system in which tissue macrophages and monocytes share 
important functional characteristics, namely, phagocytic ability and adhesiveness to glass. 
Subsequently, the histologic development of silver stains by Del Rio-Hortega defined a type of 
macrophage-related cell in the brain, the microglia. In the mid-1960s, the late Zanvil Cohn and his 
collaborators carried out seminal studies of mononuclear phagocytes leading to concepts of 
macrophage differentiation, activation, secretion, and the relationship of macrophages to antigen 
presentation and processing (for further details see Douglas, 1999). 
Adenosine has been investigated as an endogenous regulator of monocyte-macrophage functions. 
The effects produced by A3AR activation of macrophages seem to indicate an anti-inflammatory 
effect of this adenosine subtype. For example, the A3ARs suppress TNF-α release induced by the 
endotoxin CD14 receptor signal transduction pathway from human monocytes and murine J774.1 
macrophages (Le Vraux et al., 1993; McWhinney et al., 1996). Moreover in a macrophage model 
the A3AR was the prominent subtype implicated in the inhibition of LPS-induced TNF-α production 
(Sajjadi et al. 1996). This effect was associated with changes in stimulation of the activator protein-1 
(AP-1) transcription factor, whereas it was independent of MAPKs, NF-kB, PKA, PKC and PLC. 
The inhibitory effect induced by the A3AR on TNF-α production was also assessed in A3KO mice 
where the A3 agonist was unable to reduce TNF-α levels in contrast to its effect in wild type animals 
(Salvatore et al., 2000). In contrast, in BV2 microglial cells the A3-mediated inhibition of LPS-
induced TNF-α expression was associated with the inhibition of LPS-induced activation of the PI3-
kinase/Akt and NF-kB pathways (Lee et al., 2006). Recently it has been reported that in mouse 
 - 84 -
RAW 264.7 cells the A3 subtype inhibits LPS-stimulated TNF-α release by reducing calcium-
dependent activation of NF-kB and ERK 1/2 (Martin et al., 2006). In contrast, in peritoneal 
macrophages, isolated from A3 KO mice, the ability of IB-MECA to inhibit TNF-α release was not 
altered in comparison to wild type mice (Kreckler et al., 2006). In this study, the inhibitory effect 
was exerted through the activation of A2A and A2B agonists as has been recently demonstrated in 
human monocytes (Zhang et al., 2005; Haskó et al., 2007). The discrepancy observed among these 
papers cannot be the consequence of species differences, since in both cases mouse cells were used. 
Other factors, including the source of the cells and/or the inflammatory stimulus used, may be 
responsible. However in spite of these contrasting results, one of the most likely therapeutic 
applications of the regulatory role of A3 activation on TNF-α release is in the treatment of arthritis. 
More recent studies show that A3AR agonists exert significant effects in different autoimmune 
arthritis models by suppression of TNF-α production (Baharav et al., 2005). The molecular 
mechanisms involved in the inhibitory effect of IB-MECA on adjuvant-induced arthritis include 
receptor downregulation and de-regulation of the PI3K-NF-kB signalling pathway (Fishman et al., 
2006; Madi et al., 2007). Thus, A3AR activation by IB-MECA inhibited macrophage inflammatory 
protein (MIP)-1α, a C-C chemokine with potent inflammatory effects, in a model of collagen-
induced arthritis, providing the first proof of concept of the adenosine agonists utility in the 
treatment of arthritis (Szabò et al., 1998). Other anti-inflammatory effects involving A3 receptors 
activation include inhibition of fMLP-triggered respiratory burst and tissue factor expression by 
human monocytes (Broussas et al., 1999, 2002). Recently, it has been reported that, adenosine may 
be involved in ventricular remodeling by stimulating Matrix metalloproteinase-9 (MMP-9) 
production in human macrophages following A3 receptor activation (Velot et al., 2008). MMP-9 
plays an important role in ventricular remodelling after acute myocardial infarction (MI). Adenosine 
enhanced MMP-9 production when macrophages were activated by hypoxia or Toll-like receptor-4 
ligands such as lipopolysaccharide, hyaluronan, and heparan sulfate. The effect of adenosine was 
replicated by the A3 agonist IB-MECA and inhibited by silencing the A3AR through the use of RNA 
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interference. Interestingly, it was found that MMP-9 expression was higher in blood cells from 
patients with acute MI compared with healthy volunteers with important implications for therapeutic 
strategies targeting adenosine receptors in the setting of MI (Velot et al., 2008).  
In conclusion as for the role of A3 receptors in the inhibition of TNF-α production in macrophages 
discrepant results have been obtained and not only due to the different species considered. For 
example some studies attributed reduction of TNF-α  to A3 receptors either in human and mouse 
species (Sajjadi et al., 1996; McWhinney et al., 1996), whilst other found this effect to be mediated 
essentially by A2A and in minor part by A2B without the involvement of the A3 receptors again in 
both human and mouse species (Zhong et al., 2005; Kreckler et al., 2006). Therefore it is difficult in 
this case to verify the relevance of the A3 receptor-induced cellular response when other adenosine 
subtypes like A2A and A2B are also activated. As for the effects exerted by the A3 subtype in human 
monocytes and macrophages it is possible to find support for an anti-inflammatory role for this 
receptor as attested by reduction of tissue factor, oxidative burst and perhaps TNF-α  release. Also 
the recent discovery of an increase in MMP9 supports a role for A3 agonists in the therapy of 
myocardial infarction (Velot et al., 2008) (Figure 4). 
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Figure 4: Effects of A3 adenosine receptors in monocytes-macrophages 
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A3 adenosine receptor effects on dendritic cell function  
Dendritic cells are antigen-presenting cells specialized to activate naive T lymphocytes and initiate 
primary immune responses (Steinman, 1991; Hart, 1997; Banchereau,et al., 1998). Dendritic cells 
originate from hemopoietic stem cells and migrate into peripheral tissues. Dendritic cells reside in an 
immature form in unperturbed tissue, where they are capable of taking up antigens but weak at 
stimulating T cells. Under the influence of a variety of so-called danger signals including pathogens; 
dying cells; soluble CD40 ligand; cytokines such as tumor necrosis factor-α (TNF-α), interleukin 1 
(IL-1), and interleukin 6 (IL-6), or bacterial products such as LPS dendritic cells undergo a process 
of differentiation known as maturation. Thereafter, they migrate to the T-cell areas of secondary 
lymphoid organs. This maturation process is associated with reduced phagocytic and endocytic 
activity, increased membrane expression of major histocompatibility complex and co-stimulatory 
molecules, production of cytokines such as interleukin 12 (IL-12), and acquisition of potent T-cell-
stimulating functions. Depending on the conditions, dendritic cells can stimulate growth of a variety 
of T-cell subsets. In the presence of IL-12, they support the growth of Th1 cells, whereas with IL-4 
dendritic cells induce Th2-cell differentiation. In recent years it has become clear that A3 adenosine 
receptors play a role in regulation of various activities of dendritic cells. 
The expression and function of adenosine receptors in human dendritic cells has been investigated 
by using reverse transcriptase-polymerase chain reaction and functional experiments (Panther et al., 
2001). mRNA expression of the A3 receptor has been detected in immature dendritic cells together 
with A1 and A2A receptors.  Adenosine, IB-MECA and also the A1 agonist CHA, induced Ca2+ 
transients as well as actin polymerization and chemotaxis but only in immature dendritic cells. These 
findings suggest that adenosine may control proinflammatory activities of dendritic cells and 
regulate their accumulation at target sites. Maturation of dendritic cells is accompanied by a loss of 
the adenosine responses such as Ca2+ transients, actin polymerization, and migration. Unequivocal 
evidence of cell surface expression of the A3 receptor in immature dendritic cells was obtained from 
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[125I]ABMECA binding experiments. Saturation isotherms indicated a Bmax of approximately 300 
fmol/mg membrane protein, and competition for the radioligand of a variety of adenosine receptor 
ligands categorically identified the binding site as the A3 receptor (Fossetta et al., 2003). Moreover 
through fluorometric imaging plate reader (FLIPR)-based analysis of calcium mobilization it was 
shown that the A3 adenosine receptor is coupled to calcium mobilization in a pertussis toxin- 
dependent way. Interestingly these authors demonstrated that adenosine is much more potent at the 
A3 receptor than had been appreciated, being active in the low nanomolar range. Generally, 
adenosine has been regarded as a low potency agonist of the A3 receptor, with apparent affinities 
ranging from 300 nM to 1 µM (Fredholm et al., 2001). The presence of functional A3 receptors has 
been observed in XS-106, a mouse dendritic cell line, where they were coupled negatively to 
adenylyl cyclase and to stimulation of p42/p44 mitogen-activated protein kinase phosphorylation. 
Adenosine A3 receptor activation also inhibits lipopolysaccharide-induced TNF-α release from XS-
106 cells as already reported in macrophages (McWhinney et al., 1996; Dickenson et al., 2003). At 
present, the signal transduction pathway involved in adenosine A3 receptor-mediated inhibition of 
TNF-α release from XS-106 cells (and see above macrophages) is unclear. Inhibition of TNF-α 
release is usually associated with Gs-protein-coupled receptor-mediated cyclic AMP production. 
Interestingly, adenosine A3 receptors have been shown to induce an increase in intracellular calcium 
and potentiate Ca2+ currents via protein kinase A activation in A6 renal cells (Reshkin et al., 2000) 
and hippocampal CA3 pyramidal neuronal cells (Fleming and Mogul, 1997). In addition, activation 
of the adenosine A3 receptor stimulates cyclic AMP production in human eosinophils (Ezeamuzie 
and Philips, 2003). However, in XS-106 cells, Cl-IB-MECA did not stimulate cyclic AMP 
accumulation indicating that the adenosine A3 receptor is not directly coupled to Gs-protein/cyclic 
AMP accumulation in XS-106 cells. Finally, the transcript for the A3 adenosine receptor was 
elevated more than 100-fold in immature dendritic cells compared with monocyte precursors. A3 
receptor transcript was substantially diminished by LPS-induced maturation of immature dendritic 
cells. The strict dependence of A3 receptor expression on the immature cells suggests that the A3 
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receptor could also be involved in the maintenance of the immature phenotype, and its abrupt 
disappearance may be crucial for transition to a fully activated dendritic cell (Fossetta et al., 2003).  
The relevance of the A3 receptor over the other adenosine subtypes in immature human dendritic 
cells is attested to by different studies demonstrating a role for this receptor in the increase of 
intracellular calcium, actin polymerization and chemotaxis (Panther et al., 2001; Fossetta et al., 
2003) (Figure 5). However a loss of the A3 and an increase of the A2A receptor has been reported 
during maturation of dendritic cells. This switch has been interpreted as a protective effect of 
adenosine in the context of tissue injury as A2A activation plays an inhibitory role on dendritic cells 
migration. In this way adenosine could counterbalance inflammatory stimuli by delaying the arrival 
of mature dendritic cells to lymph nodes, thereby impairing the initiation of immune responses and 
reducing the potentially detrimental effects of chronic cell activation responsible for tissue damage 
and disease.  
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Figure 5: Effects of A3 adenosine receptors in dendritic cells 
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Conclusions 
The data summarized in this chapter show that A3 receptors are present in immune cells and are 
indeed involved in the physiopathologic regulation of inflammatory and immune processes. 
However results from in vitro and in vivo studies in experimental animals suggest activation of the 
A3 subtype can be both pro or anti-inflammatory depending on:  
- the cell type examined e.g. neutrophil, eosinophil, macrophage, T cell, dendritic cell;  
- the cellular model used e.g. in vitro or ex vivo; transgenic animals;  
- the response investigated e.g. degranulation, oxidative burst, migration, maturation, cytokine 
production; 
- the species considered e.g. human or animal; 
- the presence and functional roles of other adenosine receptor subtypes. 
Even though it seems that in each cell type examined contrasting effects have been reported, the 
results reviewed here offer the background for possible new therapeutic strategies for a number of 
inflammatory conditions such as sepsis, asthma and autoimmune disorders including rheumatoid 
arthritis, Crohn’s disease and psoriasis. Indeed at the moment there are A3AR agonists in clinical 
development for rheumatoid arthritis. Unfortunately there are no A3AR antagonists in clinical 
development but a number of molecules are in biological testing as therapeutic agents for asthma 
and COPD, glaucoma, and stroke, waiting to enter the clinical arena (Baraldi et al. 2008). Future 
studies aimed at elucidating new effects of the A3 subtype in the modulation of important 
inflammatory responses in the different peripheral blood cells are likely to reveal exciting new 
potential therapeutic applications of A3 agonists and/or antagonists. 
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Adenosine modulates HIF-1α, VEGF, IL-8 and foam 
cells formation in a human model of hypoxic foam cells 
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Main features of atherosclerotic lesions 
Atherosclerotic lesions are asymmetric focal thickenings of the innermost layer of the artery, the 
intima (Figure 1). They consist of cells, connective-tissue elements, lipids, and debris (Stary et al., 
1995). Blood-borne inflammatory and immune cells constitute an important part of an atheroma, the 
remainder being vascular endothelial and smooth-muscle cells. The atheroma is preceded by a fatty 
streak, an accumulation of lipid-laden cells beneath the endothelium (Stary et al., 1994). Most of 
these cells in the fatty streak are macrophages, together with some T cells. Fatty streaks are 
prevalent in young people, never cause symptoms, and may progress to atheromata or eventually 
disappear. In the center of an atheroma, foam cells and extracellular lipid droplets form a core 
region, which is surrounded by a cap of smooth-muscle cells and a collagen-rich matrix. T cells, 
macrophages, and mast cells infiltrate the lesion and are particularly abundant in the shoulder 
region where the atheroma grows (Stary et al., 1995; Jonasson et al., 1986; Kovanen et al., 1995). 
Many of the immune cells exhibit signs of activation and produce inflammatory cytokines 
(Kovanen et al., 1995; Hansson et al., 1989; van der Wal et al., 1994; Frostegard et al., 1999). 
Myocardial infarction occurs when the atheromatous process prevents blood flow through the 
coronary artery. It was previously thought that progressive luminal narrowing from continued 
growth of smooth-muscle cells in the plaque was the main cause of infarction. Angiographic studies 
have, however, identified culprit lesions that do not cause marked stenosis, (Hackett et al., 1995) 
and it is now evident that the activation of plaque rather than stenosis precipitates ischemia and 
infarction. Coronary spasm may be involved to some extent, but most cases of infarction are due to 
the formation of an occluding thrombus on the surface of the plaque (Davies et al., 1995). Plaque 
rupture is the major cause of coronary thrombosis because it exposes prothrombotic material from 
the core of the plaque — phospholipids, tissue factor, and platelet-adhesive matrix molecules — to 
the blood (Figure 1). Ruptures preferentially occur where the fibrous cap is thin and partly 
destroyed. At these sites, activated immune cells are abundant (van der Wal et al., 1994). They 
produce numerous inflammatory molecules and proteolytic enzymes that can weaken the cap and 
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activate cells in the core, transforming the stable plaque into a vulnerable, unstable structure that 
can rupture, induce a thrombus, and elicit an acute coronary syndrome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Consequences of the activation of immune cells in a coronary plaque 
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Role of endothelial activation, adhesion molecules and chemokines 
Studies in animals and humans have shown that hypercholesterolemia causes focal activation of 
endothelium in large and medium-sized arteries. The infiltration and retention of LDL in the arterial 
intima initiate an inflammatory response in the artery wall (Skalen et al., 2002) (Figure 2). LDL is a 
globular molecule with an highly-hydrophobic core consisting of polyunsaturated fatty acid and 
esterified cholesterol molecules. This core is surrounded by a shell of phospholipids, unesterified 
cholesterol and a single copy of apolipoprotein B-100 molecule. Cholesterol can move in the 
bloodstream only by being transported by lipoproteins.  Modification of LDL, through oxidation or 
enzymatic attack in the intima, leads to the release of phospholipids that can activate endothelial 
cells, (Leitinger, 2003) preferentially at sites of hemodynamic strain (Nakashima et al., 1998). 
Patterns of hemodynamic flow typical for atherosclerosis-prone segments (low average shear but 
high oscillatory shear stress) cause increased expression of adhesion molecules and inflammatory 
genes by endothelial cells (Dai et al., 2004). Therefore, hemodynamic strain and the accumulation 
of lipids may initiate an inflammatory process in the artery. The platelet is the first blood cell to 
arrive at the scene of endothelial activation (Massberg et al., 2003). Its glycoproteins Ib and IIb/IIIa 
engage surface molecules on the endothelial cell, which may contribute to endothelial activation. 
Inhibition of platelet adhesion reduces leukocyte infiltration and atherosclerosis in 
hypercholesterolemic mice (Massber et al., 2003). Activated endothelial cells express several types 
of leukocyte adhesion molecules, which cause blood cells rolling along the vascular surface to 
adhere at the site of activation (Eriksson et al., 2002). Since vascular-cell adhesion molecule 1 
(VCAM-1) is typically up-regulated in response to hypercholesterolemia, cells carrying 
counterreceptors for VCAM-1 (monocytes and lymphocytes) preferentially adhere to these sites 
(Cybulsky et al., 1991). Once the blood cells have attached, chemokines produced in the underlying 
intima stimulate them to migrate through the interendothelial junctions and into the subendothelial 
space. Genetic abrogation or pharmacologic blockade of certain chemokines and adhesion 
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molecules for mononuclear cells inhibits atherosclerosis in mice (Boring et al., 1998; Gu et al., 
1998; Lesnik et al., 2003; Lutters et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Effect of LDL infiltration on inflammation in the artery 
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Macrophages in the Developing Plaque 
A cytokine or growth factor produced in the inflamed intima, macrophage colony-stimulating factor 
(MCS-F), induces monocytes entering the plaque to differentiate into macrophages (Figure 3). This 
step is critical for the development of atherosclerosis (Smith et al., 1995) and is associated with up-
regulation of pattern-recognition receptors for innate immunity, including scavenger receptors and 
toll-like receptors (Peiser et al., 2002; Janeway et al., 2002). Scavenger receptors internalize a broad 
range of molecules and particles bearing molecules with pathogen-like molecular patterns (Peiser et 
al., 2002). Bacterial endotoxins, apoptotic cell fragments, and oxidized LDL particles are all taken 
up and destroyed through this pathway. If cholesterol derived from the uptake of oxidized LDL 
particles cannot be mobilized from the cell to a sufficient extent, it accumulates as cytosolic 
droplets. Ultimately, the cell is transformed into a foam cell, the prototypical cell in atherosclerosis. 
Toll-like receptors also bind molecules with pathogen-like molecular patterns, but in contrast to 
scavenger receptors, they can initiate a signal cascade that leads to cell activation (Janeway et al., 
2002). The activated macrophage produces inflammatory cytokines, proteases, and cytotoxic 
oxygen and nitrogen radical molecules.  
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Figure 3: Role of macrophage inflammation of the artery 
 
 
 
 
 
 - 106 - 
T-Cell activation and vascular inflammation 
Immune cells, including T cells, antigen-presenting dendritic cells, monocytes, macrophages, and 
mast cells, patrol various tissues, including atherosclerotic arteries, in search of antigen (Hansson, 
2001). A T-cell infiltrate is always present in atherosclerotic lesions (Figure 4). Such infiltrates are 
predominantly CD4+T cells, which recognize protein antigens presented to them as fragments 
bound to major-histocompatibility- complex (MHC) class II molecules. CD4+ T cells reactive to 
the disease-related antigens oxidized LDL, heat-shock protein (Caligiuri et al., 2001), and 
chlamydia proteins have been cloned from human lesions (Xu, 2002; de Boer et al., 2000). A minor 
T-cell subpopulation, natural killer T cells, is prevalent in early lesions. CD8+ T cells restricted by 
MHC class I antigens are also present in atherosclerotic lesions (Hansson, 2001). These cells 
typically recognize viral antigens, which may be present in the lesions. When the antigen receptor 
of the T cell is ligated by antigen, an activation cascade results in the expression of a set of 
cytokines, cell-surface molecules, and enzymes. The atherosclerotic lesion contains cytokines that 
promote a Th1 response (rather than a Th2 response) (Frostegard et al., 1999). Activated T cells 
therefore differentiate into Th1 effector cells and begin producing the macrophage-activating 
cytokine interferon-γ (Figure 4). Interferon-γ improves the efficiency of antigen presentation and 
augments synthesis of the inflammatory cytokines tumor necrosis factor (TNF) and interleukin-1 
(IL-1) (Szabo et al., 2003). Acting synergistically, these cytokines instigate the production of many 
inflammatory and cytotoxic molecules in macrophages and vascular cells (Hansson, 2001). All 
these actions tend to promote atherosclerosis. Cytokines of the Th2 pathway can promote 
antiatherosclerotic immune reactions (Binder et al., 2004). However, they may also contribute to the 
formation of aneurysms by inducing elastolytic enzymes (Shimizu et al., 2004). Therefore, 
switching the immune response of atherosclerosis from Th1 to Th2 may not necessarily lead to 
reduced vascular disease. T-cell cytokines cause the production of large amounts of molecules 
downstream in the cytokine cascade. As a result, elevated levels of interleukin- 6 (IL-6) and C-
reactive protein may be detected in the peripheral circulation. In this way, the activation of a limited 
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number of immune cells can initiate a potent inflammatory cascade, both in the forming lesion and 
systemically. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Effects of T-Cell activation on plaque inflammation 
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Mechanisms of plaque rupture 
What causes a silent atherosclerotic lesion to rupture? 
Activated macrophages, T cells, and mast cells at sites of plaque rupture (Kovanen et al., 1995; van 
der Wal et al., 1994; Moreno et al., 1994) produce several types of molecules — inflammatory 
cytokines, proteases, coagulation factors, radicals, and vasoactive molecules — that can destabilize 
lesions. They inhibit the formation of stable fibrous caps, attack collagen in the cap, and initiate 
thrombus formation (Hansson et al., 1989; Saren et al., 1996; Mach et al., 1997). All these reactions 
can conceivably induce the activation and rupture of plaque, thrombosis, and ischemia. Two types 
of proteases have been implicated as key players in plaque activation: matrix metalloproteinases 
(MMPs) and cysteine proteases (Jons et al., 2003; Liu et al., 2004). Several members of these 
families of enzymes occur in the plaque and may degrade its matrix. MMP activity is controlled at 
several levels: inflammatory cytokines induce the expression of MMP genes, plasmin activates 
proforms of these enzymes, and inhibitor proteins (tissue inhibitor of metalloproteinase) suppress 
their action. Similarly, cysteine proteases are induced by certain cytokines and checked by 
inhibitors termed “cystatins” (Liu et al., 2004). Several of these molecules play decisive roles in the 
formation of aneurysms, as shown by experiments in gene-targeted mice. However, mechanistic 
studies in models of atherosclerosis have yielded complex results, with certain MMPs reducing 
rather than increasing the size of the lesions. At the same time, these enzymes clearly affect the 
composition of plaque. Therefore, they may represent future therapeutic targets. Study of plaque 
rupture in animal models should be helpful in determining the role of these proteases in the 
activation of plaque and myocardial infarction. 
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Risk Factors 
Reducing risk factors is the primary clinical approach for the prevention of cardiovascular disease 
(Kavey et al., 2006). Risk factors of cardiovascular disease are divided in modifiable and non 
modifiable.  Modifiable risk factors for atherosclerosis include tobacco use, high cholesterol levels, 
high blood pressure, diabetes, obesity, physical inactivity, and diet. One of the most important 
modifiable risk factors is smoking. A smoker‘s risk of developing coronary artery disease is directly 
related to the amount of tobacco smoked daily. The risk of a heart attack is increased threefold in 
men and sixfold in women who smoked (Stemme et al., 1995) or more cigarettes per day compared 
with nonsmokers. Tobacco use decreases the level of high-density lipoprotein (HDL) cholesterol 
and increases the level of low-density lipoprotein (LDL) cholesterol. An high level of LDL 
cholesterol is another important modifiable risk factor, so diet become very important. Cholesterol 
levels also increase with age and are normally higher in men than in women, although levels 
increase in women after menopause.  Diabetes is yet another risk factor for atherosclerosis of 
growing importance. The hyperglycemia associated with diabetes can lead to modification of 
macromolecules, for example, by forming advance glycation end products (AGE)(Schmidt et al., 
1999) that can augment the production of proinflammatory cytokines and other inflammatory 
pathways in vascular endothelial cells. Beyond the hyperglycemia, the diabetic state promotes 
oxidative stress mediated by reactive oxygen species and carbonyl groups (Baynes et al., 1999). 
Obesity not only predisposes to insulin resistance and diabetes, but also contributes to atherogenic 
dyslipidemia. High levels of free fatty acids originating from visceral fat reach the liver through the 
portal circulation and stimulate synthesis of the triglyceride-rich lipoprotein VLDL by hepatocytes. 
Adipose tissue can also synthesize cytokines such as TNF-α and IL-6 (Yudkin et al., 1999). In this 
way obesity itself promotes inflammation and potentiates atherogenesis independently of effects on 
insulin resistance or lipoproteins. Risk factors that cannot be modified include having a family 
history of early atherosclerosis, advancing age, and male sex. Men have a higher risk than women, 
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although women who have coronary artery disease are more likely to die than men who have the 
disease (Rosamond et al., 2007). 
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INTRODUCTION 
Macrophage foam cell formation is an important process in atherosclerotic plaque development 
(Pennings et al., 2006). Atherosclerosis is initiated by dysfunction of endothelial cells at lesion-prone 
sites in the walls of arteries, which results in monocyte infiltration into the arterial intima. These 
cells differentiated into macrophages, which then internalize large amounts of oxidized low-density 
lipoprotein forming cholesterol-laden macrophages called “foam cells” (FC), which in turn give rise 
to fatty streaks in the arterial wall (Lusis, 2000). As the atherosclerotic lesion develops, the arterial 
wall tickness increases and oxygen diffusion into the intima is markedly reduced. These hypoxic 
regions contain large number of FC revealing that these cells experience hypoxia during the 
development of atherosclerotic lesions (Bjornheden et al., 1999; Murdoch et al., 2005). Hypoxia-
inducible factor-1 (HIF-1), the most important factor involved in the cellular response to hypoxia, is 
an heterodimeric transcription factor composed of an inducibly-expressed HIF-1α subunit and a 
constitutively-expressed HIF-1β subunit (Semenza, 2001). It is well established that HIF plays a 
major role in vascular endothelial growth factor (VEGF) expression and angiogenesis, mediating 
important alterations associated with atherogenesis and angiogenic activity of macrophages (Paul et 
al., 2004; Sluimer et al., 2008). Moreover, under atherogenic conditions, the high expression of HIF-
1 in macrophages promotes FC formation and atherosclerosis (Jiang et al., 2007). 
Recently, it has been shown that another angiogenic chemokine, Interleukin-8  (IL-8) is up-
regulated by FC located in hypoxic areas in rabbit and human atherosclerotic plaques (Murdoch et 
al., 2005). Hypoxia-induced secretion of IL-8 from FC may lead to the recruitment of smooth 
muscle, vascular endothelial and T cells into the atherosclerotic plaques and thus to plaque 
progression (Wang et al., 1996). It has been also demonstrated that in vascular endothelium, under 
hypoxia, IL-8 expression  is increased by HIF (Conway EM., 2003/2004; Kim et al., 2006). 
However, the relationships between HIF and IL-8 has been questioned by other authors (Loboda et 
al., 2006). 
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Adenosine (Ado) is a proangiogenic purine nucleoside released from ischemic and hypoxic tissues. 
Under these conditions, it  is released into the extracellular space and signals through the stimulation 
of four extracellular  G protein-coupled receptors named A1, A2A, A2B, and A3 (ARs) (Jacobson et 
al., 2006). All the four adenosine subtypes have been recently associated to the modulation of 
angiogenesis. Therefore due to the link between ado, inflammation and angiogenesis and the 
increasing evidence that these factors play a role in atherogenesis we thought to investigate HIF-1α, 
VEGF, IL-8 and FC formation by ado receptors in human macrophages and in an “in vitro” model 
of human FC (Yu et al., 2003). 
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EXPERIMENTAL PROCEDURES 
Materials 
5-N-(4-methoxyphenyl-carbamoyl)amino-8-propyl-2(2furyl)-pyrazolo-[4,3e]-1,2,4-triazolo [1,5-c] 
pyrimidine ([3H]MRE 3008F20, specific activity 67 Ci mmol-1), N-benzo[1,3]dioxol-5-yl-2-[5-
(1,3-dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl-oxy] 
acetamide] ([3H]MRE 2029F20, specific activity 123 Ci mmol-1) were obtained from Amersham 
International (Buckinghamshire, UK), (4-(2-[7-amino-2-(2-furyl)-[1,2,4]triazolo-
[2,32][1,3,6]triazinyl-amino] ethyl)-phenol) ([3H]ZM 241385, specific activity 20 Ci mmol-1) was 
purchased from Tocris (Boston, Mass; USA) and 1,3-dipropyl-8-cyclopentyl-xanthine 
([3H]DPCPX, specific activity 120 Ci mmol-1) was derived from NEN Research Products (Boston, 
Mass; USA). 7-(2-phenylethyl)-2- (2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]-pyrimidine (SCH 
58261), 1-Deoxy-1-[6-{4- [(phenylcarbamoyl)-methoxy]phenylamino}-9H-purin-9-yl]-N-ethyl-b-
D-ribofuranuronamide (Compound 24) were synthesized by Prof. P.G. Baraldi (Department of 
Pharmaceutical Sciences, University of Ferrara, Italy). Phorbol myristate acetate (PMA), erythro-9-
(2-hydroxy-3- nonyl)adenine (EHNA), cyclohexyl-adenosine (CHA), 2-[p-(carboxyethyl)-
phenethylamino]- NECA (CGS 21680), N6 -(3iodobenzyl)-2-chloroadenosine-5'N-
methyluronamide (Cl-IB-MECA), rapamycin were purchased by Sigma Aldrich (Milano, Italy). 
The antibodies for A1, A2A, A2B adenosine receptor subtypes were purchased from Alpha 
Diagnostic (S. Antonio, Texas, USA) and the antibody for A3 was from AVIVA System Biology 
(Milano, Italy). Human anti-HIF-1a and HIF-1b antibodies were obtained from BD Transduction 
Laboratories (Milano, Italy). The Anti- ACTIVE_ mitogen-activated protein kinase anti-ERK1/2 
(pAb) was from Promega (Milano, Italy). Phospho-Akt (Ser473) and phospho-p38 (Thr180/Tyr182) 
were purchased from Cell Signaling Technology (Milano, Italy). Ficoll-Hypaque was obtained by 
Amersham Pharmacia Biotech AB. The assays-on-demandTM. Gene expression Products NM 
000674, NM 000675, NM 000676 and NM 000677 for A1, A2A, A2B and A3 adenosine subtypes 
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and the assays-on-demandTM Gene expression Products Hs00936368_m1, Hs00173626_m1, 
Hs00174103_m1, Hs00765620_m1, Hs99999906_m1, for HIF-1_, VEGF, IL-8, Aldolase A and 
Phosphoglycerate kinase (PGK) were purchased from Applera (Milano, Italy). A1, A2A, A2B, 
A3AR, HIF-1_ small interfering RNAs (siRNAs) and HIF-2_ antibody were from Santa Cruz 
Biotechnology (Santa Cruz, CA). Nuclear Extract Kit and HIF-1_ binding activities were from 
Active Motif (Belgium). All other reagents were of analytical grade and obtained from commercial 
sources. 
 
Methods 
Cell culture 
The human myelomonocytic cell line U937 was obtained from ATCC and maintained in RPMI 
1640 medium supplemented with 10% fetal calf serum, L-glutamine (2 mM), 100 U/ml penicillin, 
100 µg/ml streptomycin, at 37C° in 5% CO2/95% air. 
 
Preparation of human macrophages (HM) from peripheral blood 
 Peripheral blood mononuclear cells were isolated from buffy coats by the Ficoll-Hypaque gradient 
(Amersham Pharmacia Biotech AB) and centrifuged at 2200 rpm for 15 min. (Gessi et al., 2004). 
The human peripheral blood mononuclear cells were isolated and removed from the Ficoll-Hypaque 
gradients. Subsequently, they were washed in 0.02 M phosphate-buffered saline at pH 7.2 
containing 5 mM MgCl2 and 0.15 mM CaCl2. Finally, they were decanted into a culture flask in 
RPMI 1640 medium containing 2 mM glutamine, 5% human AB serum (Sigma), 100 U/ml 
penicillin and 100 µg/ml streptomycin and placed in a humidified incubator (5% CO2). Monocytes 
were selected by adhesion and differentiated into HM over 5-7 days.  
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Hypoxic treatment 
 Hypoxic exposures were done in a modular incubator chamber and flushed with a gas mixture 
containing 1% O2, 5% CO2 and balance N2 (MiniGalaxy, RSBiotech, Irvine, Scotland). 
 
FC formation 
U937 cells were induced to differentiate into HM by treatment with 40 nM phorbol myristate 
acetate (PMA) for 72 hours. Before use oxLDL (Intracel, Frederick, MD) were dialyzed against 1 
liter of 0.15 M sodium chloride and 0.3 mM EDTA (pH 7.4) for 12 h at 4°C, then against RPMI 
1640 medium (two changes, 1 liter/each change) for 24 h at 4°C. All dialysis was carried out with 
Pierce Slide-A-Lyzer cassettes (10,000 molecular wheight cut-off). After dialysis, lipoproteins were 
sterilized by passing them through a 0.45 µm (pore-size) filter and added (50 or 100 µg/ml) to 
PMA-treated U937 cells for 48 h in serum-free RPMI (Kruth et al., 2002). Then all treatments to the 
cells with ado were carried out in the presence of the adenosine deaminase (ADA) inhibitor, 
erythro-9-(2- hydroxy-3-nonyl)adenine (EHNA) 5 µM and those with ado agonists were performed 
in the presence of ADA.  
 
Real-time RT-PCR 
Total cytoplasmic RNA was extracted by the acid guanidinium thiocyanate phenol method. 
Quantitative real-time RT-PCR assay was performed as previously described (Higuchi et al., 1993). 
The assays-on-demandTM Gene expression Products NM 000674, NM 000675, NM 000676 and 
NM 000677 for A1, A2A, A2B and A3 ARs were used, respectively. Quantification of ARs messages 
was made by interpolation from standard curve of Ct values generated from the plasmid dilution 
series (Gessi et al., 2007). Analogue results were obtained when the expression level of ARs was 
normalized to that of β-actin. For the real-time RT-PCR of HIF-1α, VEGF, IL-8, Aldolase A and 
PGK the assays-on-demandTM Gene expression Products Hs00936368_m1, Hs00173626_m1, 
Hs00174103_m1, Hs00765620_m1, Hs99999906_m1 were used, respectively. For the real-time 
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RT-PCR of the reference gene the endogenous control human β-actin kit was used, and the probe 
was fluorescent labeled with VICTM (Applera). 
 
Binding experiments 
 Binding assays were carried out as reported previously (Gessi et al., 2007). In saturation 
experiments, membranes (70 µg of protein/assay) were incubated with 50 mM Tris HCl buffer (10 
mM MgCl2 for A2A; 10 mM MgCl2, 1 mM EDTA, 0.1 mM benzamidine for A2B and 10 mM 
MgCl2, 1 mM EDTA for A3) pH 7.4 and increasing concentrations of 1,3-dipropyl-8-
cyclopentylxanthine ([3H]DPCPX) (0.4-40 nM); (4-(2-[7-amino-2-(2-furyl)-[1,2,4]triazolo-[2,32]-
[1,3,6]- triazinyl-amino] ethyl)-phenol) ([3H]ZM 241385) (0.3-30 nM); N-benzo[1,3]dioxol-5-yl-2-
[5-(1,3- dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl-oxy]-
acetamide] ([3H]MRE 2029F20) (0.4-40 nM); 5-N-(4-methoxyphenyl-carbamoyl)amino-8-propyl-
2-(2furyl)- pyrazolo-[4,3e]-1,2,4-triazolo [1,5-c] pyrimidine ([3H]MRE 3008F20) (0.4-40 nM) to 
label A1, A2A, A2B and A3 ARs, respectively. The filter bound radioactivity was counted on Top 
Count Microplate Scintillation Counter (efficiency 57%) with Micro-Scint 20. 
 
Western Blot Analysis 
Cells were harvested and washed with ice-cold PBS containing 1 mM sodium orthovanadate. Cells 
were then lyzed in Triton lysis buffer. Equivalent amounts of protein (40 µg) were subjected to 
electrophoresis on 10% sodium dodecyl sulfate–acrylamide gel. The gel was then electroblotted on 
to a nitrocellulose membrane. Then the membranes were probed with specific antibodies (Merighi 
et al., 2005). ARs were evaluated by using specific antibodies towards human A1, A2A, A2B (Alpha 
Diagnostic) and A3 ARs (Aviva) (1:1000 dilution). In experiments aimed to detect HIF, western 
blot analyses were performed using antibody against HIF-1α (1:250 dilution) (BD Biosciences), 
HIF-2α (1:1000) (Novus Biologicals) and HIF-1β (1:1000 dilution) (BD Biosciences) in 5% non-fat 
dry milk in PBS/0.1% Tween-20 overnight at 4°C. For detection of phosphorylated proteins 
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antibodies specific for phosphorylated (Thr183/Tyr185) p44/p42 MAPK (1:5000 dilution), 
phosphorylated (Thr180/Tyr182) p38 MAPK (1:1000 dilution) and phosphorylated Akt (Ser473) 
(1:1000 dilution) were used. The protein concentration was determined using BCA protein assay kit 
(Pierce, Rockford, IL). Tubulin (1:250) was used to ensure equal protein loading. Immunoreactivity 
was assessed and quantified by using a VersaDoc Imaging System (Bio-Rad). 
 
HIF-1 DNA binding activity 
Nuclear extracts from U937, FC and HM were prepared by using the Nuclear Extract Kit (Active 
Motif) and HIF-1α binding activities in the nuclear extracts were detected by using an ELISA-based 
HIF binding kit (TransAM™ HIF-1, Active Motif) according to the manufacturer’s 
recommendations. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
 The levels of VEGF and IL-8 protein secreted by the cells in the medium were determined by 
VEGF and IL-8 ELISA kits (R&D Systems) according to the manufacturer’s instructions. The data 
were presented as mean ± SD from four independent experiments. 
 
Knockdown of ARs and HIF-1α by small interfering RNA (siRNA) 
 FC were plated in six-well plates and grown to 50–70% confluence before transfection. 
Transfection of siRNA was performed at a concentration of 100 nM using Lipofection 2000 in 
Opti-MEM (Invitrogen). A non-specific random control ribonucleotide sense strand (5’-ACU CUA 
UCU GCA CGC UGA CdTdT-3’) and antisense strand (5’-dTdT UGA GAU AGA CGU GCG 
ACU G-3’) were used under identical conditions as already reported (Merighi et al., 2005). A1, A2A, 
A2B, A3AR and HIF-1α siRNAs were from Santa Cruz Biotechnology (Santa Cruz, CA). 
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Oil red O-stain analysis 
Treatment of PMA-differentiated U937 cells with ado and ado ligands was performed before 
addition of oxLDL. After exposition to oxLDL under hypoxia for 24 h cells were fixed in saline-
buffered 4% paraformaldehyde solution for 15 min and then air dried. Oil red O (in 60% 
isopropanol) staining was done for 15 min essentially as described before (Kalayoglu et al., 1998). 
Cells were viewed under a bright-field microscope in 100 X fields using a Nikon’s Eclipse E800 
microscope. FC were defined as macrophages in which cytoplasm was filled with Oil Red O-
stainable lipid droplets. 
 
MTS Assay 
The MTS assay was performed to determine foam cells viability according to the manufacturer's 
protocol from the CellTiter 96 AQueous One Solution (Promega) cell proliferation assay. Cells 
(105) were plated in 24-multiwell plates; 500 µl of complete medium was added to each with ado. 
The cells were then incubated for 24 h. At the end of the incubation period, MTS solution was 
added to each well. The optical density of each well was read on a spectrophotometer at 570 nm. 
Experiment was repeated three times. 
 
Statistical analysis 
All values in the figures and text are expressed as mean ± standard error (S.E.) of N observation 
(with N ³ 3). Data sets were examined by analysis of variance (ANOVA) and Dunnett’s test (when 
required). A P-value less than 0.05 was considered statistically significant. 
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RESULTS 
Expression of ARs mRNA in U937, HM and FC  
mRNA expression of ARs was evaluated in U937, HM and FC in normoxia and hypoxia. Hypoxia 
induced a significant increase of A2BARs in all the three cellular models investigated, whilst did not 
change the level of the other ARs  (Figure 5 A-D).  
 
Expression of ARs protein in U937 cells, HM and FC  
The protein evaluation of all ARs was examined, through immunoblots, in U937, HM and FC in 
normoxia and hypoxia. We observed the presence of all ARs in the cells investigated according to 
mRNA data, as reported in Figure 5 E-H. These results were also confirmed by [3H]DPCPX, 
[3H]ZM 241385, [3H]MRE 2029F20 and [3H]MRE 3008F20 radioligands, used in receptor binding 
studies to evaluate affinity and density values of A1, A2A, A2B and A3 ARs, respectively (Table 1).  
 
Ado induces HIF-1α protein accumulation  
To evaluate the effect of ado on HIF-1α FC, HM and U937 cells (Figure 6) were incubated with 
ado 100 µmol/L in normoxia and hypoxia. In hypoxia ado stimulated HIF-1α accumulation, time-
dependently, in all cells investigated. As for normoxia, ado effect slightly appears after 24 hours in 
FC, whilst HIF-1α protein was undetectable in HM and in U937 cells. In FC the effect was similar 
with 50 or 100 µg/mL of oxLDL (data not shown), therefore the concentration of 50 µg/mL was 
used in all experiments. No changes in cell viability were observed after treatment of cells with ado 
100 µmol/L for 24 h of hypoxia (data not shown). Furthermore, treatment of ado stimulated, in a 
time-dependent way, HIF-1α DNA binding activity in hypoxia and also induced a minor but 
statistically significant effect in normoxia in FC, HM and U937 cells (Figure 7). Ado did not 
affected HIF-1α mRNA levels in normoxia and after 2 hours hypoxia whilst it induced a slight 
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increase of 1.6±0.1, 1.9±0.1 and 1.5±0.1 fold after 4, 8, 24 hours of hypoxia, respectively (P<0.05 vs 
control); following addition of actinomycin D (actD), ado did not increase HIF-1α mRNA excluding 
a role in mRNA stability (Figure 8A). The lack of mRNA modulation after 2 h, time at which ado 
start to affect protein increase, suggests that ado does not affect transcription. Furthermore, we 
evaluated the ado-induced regulation of HIF-2α in hypoxia. Figure 8B shows that ado slightly 
increased HIF-2α and this effect was blocked by actD suggesting that at variance with HIF-1α,  HIF-
2α was transcriptionally regulated by ado. 
Then we investigated the ado modulation of HIF-1α protein stability in hypoxia and normoxia. Ado 
in normoxia, at variance with hypoxia, increases HIF-1α stability; furthermore rapamycin, inhibitor 
of mTOR pathway, reduced ado effect suggesting also an increase in translation (Figure 9A-C). 
However as the ado effect on HIF-1 was most evident in hypoxia all the other experiments were 
carried out in this condition for 4 hours. 
 
Involvement of ARs in ado-induced HIF-1α expression 
To evaluate which AR was involved in the ado-induced HIF-1α expression we treated FC with 
antagonists of ARs before addition of ado in hypoxia (Figure 10A). Ado effect was partially 
antagonized by 100 nmol/L DPCPX, SCH 58261, MRE 2029F20 and MRE 3008F20 suggesting the 
involvement of A1, A2A, A2B and A3 ARs, respectively. Therefore we evaluated the effect of high 
affinity agonists, CHA, CGS 21680, Compound 24 (Baraldi et al., 2007) and Cl-IB-MECA on HIF-
1α accumulation. Probes selectivity is provided in table 2. All the agonists were able to induce HIF-
1α in FC (Figure 10B). Analogous results were obtained in U937 cells and in HM (data not shown). 
Therefore in the second part of the work we focused our attention on FC. 
To further ascertain the involvement of the different ARs in the ado-induced HIF-1α accumulation 
we knocked-down ARs. After 48 and 72 hours posttransfection with siRNA targeting each AR, 
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mRNA and protein levels were significantly reduced; the specificity of a given siRNA to the other 
AR subtypes is also shown in figure 11. Treatment of cells with siRNAs for A1, A2A, A2B and A3 
subtypes reduced the effect of ado on HIF-1α modulation supporting again a role for all ado 
subtypes in this effect; silencing of all ARs together abrogated the ado-mediated increase of HIF-1α 
protein (Figure 10C). 
 
Involvement of MAPK and Akt pathways in ARs-induced modulation of HIF-1α 
To investigate the role of MAPK and Akt kinases in ARs-induced HIF-1α accumulation, we 
performed experiments with U0126, SB202190 and SH-5, inhibitors of MEK1/2, p38 MAPK, and 
Akt respectively, in FC. All the blockers were able to abrogate the effect induced by A1, A2A and 
A2B agonists, whilst the A3-mediated HIF-1α accumulation was antagonized only by U0126 (Figure 
12A). Addition of CHA, CGS 21680 and Compound 24 induced a concentration-dependent increase 
of pERK1/2, pp38 and pAkt, whilst Cl-IB-MECA was involved only in ERK1/2 phosphorylation 
(Figure 12B).  
 
ARs induce VEGF increase in Hypoxia 
We tested VEGF production by FC after ado treatment for 24 h of hypoxia. Ado 100 µmol/L 
increased VEGF levels of 165±10% and the effect was strongly reduced by MRE 2029F20 and 
MRE 3008F20 100 nmol/L suggesting the involvement of A2B and A3ARs and inhibited to a lesser 
extent by the A2A antagonist (Figure 13A). DPCPX 100 nmol/L produces a moderate blunting of 
ado-induced VEGF release, but at this concentration it can have antagonistic actions against A2B 
receptors see supplemental Table 2. Indeed a lower dose of DPCPX 10 nmol/L did not reduce ado 
effect (161±10%). U0126 and SB202190 followed by SH-5 were able to block the ado increase on 
VEGF levels. Treatment of the cells with siRNA of HIF-1α abrogated the VEGF increase induced 
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by ado suggesting that the nucleoside was acting through HIF-1α modulation (Figure 13B). The 
increase induced by ado 100 µmol/L on VEGF was also observed at mRNA level (2.4±0.2 fold of 
increase, P<0.05 vs control). Other HIF-1α-responsive genes, aldolase and PGK were  increased at 
mRNA level after ado treatment for 24 hours of 4.5±0.2 and 1.8±0.2 fold, respectively and the effect 
was abrogated in the presence of HIF-1α siRNA, 1.1±0.1  and 1.0±0.1 fold, respectively (P<0.05 vs 
control). 
 
A2BAR induces IL-8 increase in Hypoxia 
We tested IL-8 production by FC after ado treatment for 24 h in hypoxia. Ado 100 µmol/L increased 
IL-8 levels of 158±10 % and the effect was blocked by MRE 2029F20 or A2B silencing, but not by 
DPCPX, SCH 58261 and MRE 3008F20 (Figure 13C-D). A dose-response curve of Compound 24 
revealed an EC50 value of 58±6 nmol/L for stimulation of IL-8 secretion. The effect of Compound 
24 1 µmol/L (142±8% of IL-8 secretion) was completely blocked by MRE 2029F20 (102±6% of IL-
8 secretion). All these data suggest the involvement of A2B subtype in this response. U0126, 
SB202190 and SH5 were able to revert the ado increase on IL-8 levels suggesting a role for ERK 
1/2, p38 and Akt pathways (Figure 13D). Finally, treatment of cells with siRNA of HIF-1α for 72 
hours before stimulation with ado shows that IL-8 modulation was not affected by HIF-1α silencing 
(Figure 13D). IL-8 was not altered by ado at mRNA level (1.14±0.1 fold of increase versus control). 
 
Oil red O staining in FC 
U937 cells without oxLDL did not contain high levels of neutral lipids and were not stained with Oil 
red O, a dye specific for neutral lipids (Figure 14). After treatment of U937 cells with 50 µg/mL ox-
LDL for 24 h, we observed FC formation characterized by large cytoplasmic lipid droplets. This 
effect was increased after incubation with ado 100 µmol/L, not significantly affected by DPCPX and 
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SCH 58261 and strongly blocked by MRE 2029F20 and MRE 3008F20 antagonists and HIF-1α 
silencing, suggesting the involvement of HIF-1α and A2B and A3 ARs in the ado-induced FC 
formation. Also the high affinity A2B and A3 agonists were able to increase FC formation (Figure 
14). 
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Figure 5 - mRNA and protein expression of ARs in U937 cells, HM and FC in normoxia (N) 
and hypoxia (H): Bargraph showing µg mRNA/µg total RNA of human A1, A2A, A2B and A3 ARs 
(A-D, respectively). ARs detection by western blot analysis (E-H). Cellular extracts were prepared 
and subjected to immunoblot assay using anti-A1, A2A, A2B and A3 antibodies. Tubulin shows equal 
loading protein. Values are the means and vertical lines S.E. of the mean of four separate 
experiments performed in triplicate. *P<0.05 compared with normoxia. 
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Table 1- Affinity (KD, nM) and density (Bmax, fmol/mg of protein) values of A1, A2A, A2B and A3. 
ARs evaluated through [3H]DPCPX, [3H]ZM 241385, [3H]MRE 2029F20 and [3H]MRE 3008F20 
radioligands, respectively, in PMA-treated U937, HM and FC cells in normoxia (N) and hypoxia 
(H). 
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Figure 6 - Time course of HIF-1α modulation induced by ado. Effect of 100 µmol/L Ado on 
HIF-1α protein expression (panel A-C) in FC, HM and U937 cells, respectively,  in normoxia (N) 
and hypoxia (H). HIF-1β shows equal loading protein. Densitometric quantification of HIF-1α 
western blots is the mean ± S.E. values (N=3); *P<0.05 compared with 24 h normoxia in FC or with 
2 h hypoxia in HM and U937 cells in the absence of Ado; #P<0.05 compared with cells in the 
absence of Ado at each time.  
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Figure 7 - HIF-1α  DNA binding activity (panel A-C) in FC, HM and U937 cells, respectively,  in 
normoxia (N) and hypoxia (H). DNA binding activity data are means ± S.E (N=3); *P<0.05 
compared with 24 h normoxia in FC and U937 cells or with 4 h normoxia in HM in the absence of 
Ado; #P<0.05 compared with cells in the absence of Ado at each time. 
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Figure 8 - Effect of actinomycin D (ActD) on HIF-1α and HIF-2α in foam cells. Real-time 
RTPCR analysis of HIF-1α mRNA level. Total RNA was extracted from cells treated in the absence 
or in the presence of Ado for 2, 4, 8, 24 h hypoxia before and after addition of ActD (10 µg/ml). 
Data were expressed as fold of increase vs control arbitrarily fixed as 1 (cells in the absence of 
Ado). *P<0.05 compared with control (A). Western blot analysis of HIF-1α  and HIF-2α protein 
level after treatment with 100 µmol/L Ado in the absence and in the presence of ActD. 
Densitometric quantification of western blots is the mean ± S.E. values (N=3); *P<0.05 compared 
with control (cells in the absence of Ado) (B). 
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Figure 9 - Effect of cycloheximide (CHX) on induction of HIF-1α in foam cells. Western blot 
analysis of HIF-1α protein level. Cells were treated in hypoxia without or with 100 µmol/L ado for 
4 hours, 1 µmol/L CHX was added to inhibit new HIF-1α protein synthesis, and incubation was 
continued for 0.25, 0.5, 1, 2 and 4 h (A). Densitometric quantification of HIF-1α western blots is the 
mean ± S.E. values (N=3); *P<0.05 compared with control (cells in the absence of Ado and CHX 
treated in hypoxia for 4 h), # P<0.05 compared with control (cells in the absence of CHX treated in 
hypoxia plus Ado for 4 h) (B). Effect of CHX and 100 nmol/L rapamycin on HIF-1α DNA binding 
activity induced by ado in normoxia (C). Cells were treated in normoxia without or with 100 
µmol/L ado for 8 hours, 1 µmol/L CHX was added to inhibit new HIF-1α protein synthesis, and 
incubation was continued for 0.25, 0.5 and 1 h. Cells were treated in normoxia without or with 100 
µmol/L ado for 8 hours in the presence of rapamycin. Nuclear extracts were isolated and subjected 
to a colorimetric assay. Means ± S.E (N=3); *P<0.05 versus control (cells in the absence of CHX 
treated in normoxia plus Ado for 8 h). 
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Figure 10 – Effect of AR ligands and ARs silencing on HIF-1α protein increase.  Effect of Ado 
on HIF-1α protein accumulation and antagonism by 100 nmol/L MRE 3008F20 (selective A3 
antagonist), SCH 58261 (selective A2A antagonist), DPCPX (A1 antagonist) and MRE 2029F20 
(selective A2B antagonist) (A). HIF-1α accumulation in the absence (line 1, control) and in the 
presence of AR agonists (nmol/L ) 10, 100  CHA (A1 agonist, lines 2, 3); 500, 1000 CGS 21680  
(A2A agonist, lines 4, 5); 10, 100  Compound 24 (A2B agonist, lines 6,7); 10, 100  Cl-IB-MECA (A3 
agonist, lines 8, 9) (B). Ado effect on HIF-1α  in the absence (line 2) and in the presence of siRNA 
of A1, A2A, A2B, A3 ARs (lines 3, 4, 5, 6, respectively). Ado effect in the presence of siRNA of A1, 
A2A, A2B, A3 ARs together (siAdoRs)  (line 7); cells transfected  with control (C) ribonucleotides for 
72 h (line 1) (C). Densitometric quantification of western blots is the mean ± S.E. values (N=3); 
*P<0.05 compared with the control; **P<0.05 compared with Ado.  
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Table 2-Affinity (Ki, nM) of selected adenosine receptor agonists and antagonists to A1, A2A, A2B 
and A3 adenosine receptors. 
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Figure 11 - ARs silencing by siRNA transfection in FC. Relative ARs mRNA 
quantification,related to β-actin mRNA, by real-time RT-PCR; FC were transfected with siRNA of 
A1, A2A, A2B and A3 ARs (A-D, respectively) and cultured for 24, 48 and 72 h. Plots are mean ± 
S.E. values (N = 3); *P < 0.05 compared with the control (time = 0). Western blot analysis using 
anti A1, A2A, A2B and A3 receptor polyclonal antibodies (E-H, respectively), of protein extracts from 
FC treated with siRNA of each AR subtype and cultured for 24, 48 and 72 h. Tubulin shows equal 
loading protein. Specificity of adenosine receptors siRNAs (I). Western blot analysis using anti A1, 
A2A, A2B and A3 receptor polyclonal antibodies of protein extracts from FC transfected with control 
ribonucleotides (ctr.) or with siRNA of each AR subtype and cultured for 72 h. Tubulin shows equal 
loading protein. 
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Figure 12 - Role of intracellular kinases in HIF-1α modulation induced by AR activation. FC 
were treated with  nmol/L 100 CHA , 500 CGS 21680, 100 Compound 24, 100 Cl-IB-MECA in the 
absence (lines 5, 9, 13, 17, respectively) and in the presence of (1 µmol/L)  U0126 (lines 6, 10, 14, 
18, respectively), SB202190 (lines 7, 11, 15, 19, respectively), SH-5 (lines 8, 12, 16, 20). Line 
1(control), line 2 (U0126), line 3 (SB202190), line 4 (SH-5)  (A). Effect of ado agonists (nmol/L) 
10, 100  CHA (lines 2, 3); 500, 1000  CGS 21680 (lines 4, 5); 10, 100  Compound 24 (lines 6, 7); 
10, 100   Cl-IB-MECA (lines 8, 9) on ERK1/2, p38 and Akt phosphorylation (B). Densitometric 
quantification of western blots is the mean ± S.E. values (N=4); *P<0.05 compared with the control. 
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Figure 13 - Effect of ado on VEGF and IL-8 secretion. VEGF and IL-8 levels in FC treated with 
100 µmol/L Ado in the absence and in the presence of 100 nmol/L DPCPX, SCH 58261, MRE 
3008F20 and MRE 2029F20 (A, C). Role of 1 µmol/L ERK1/2, p38, Akt inhibitors and siRNA of 
HIF-1α in VEGF secretion induced by Ado (B); siRNA of  HIF-1α was compared with cells 
transfected  with control ribonucleotides for 72 h (-siRNA). Role of 1 µmol/L ERK1/2, p38, Akt and 
siRNA of  HIF-1α and A2B receptors in IL-8 secretion induced by Ado (D). Bargraphs are the means 
and vertical lines S.E. of the mean of four separate experiments performed in triplicate. *P<0.05 
compared with control;  #P<0.05 compared with ado.  
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Figure 14 – Induction of FC formation by the U937 cells. Cells were stained for lipids with Oil 
red O in parallel cultures by incubation in the absence (A) or in the presence (B) of ox-LDL (50 
µg/ml) followed by paraformaldehyde fixation. Effect of 100 µmol/L Ado on FC formation (C) and 
effect of 100 nmol/L ARs blockers (D-G) and HIF-1 silencing (H). Effect of A2B and A3 agonists on 
FC formation (I-L). Cells were viewed under a bright-field microscope in 100 X fields using a 
Nikon’s Eclipse E800 microscope. Bargraph data expressed as the percentage of foam cells/total 
number of cells plated, are the mean ± S.E. values (N=3);  *P<0.05 vs cells in the absence of oxLDL 
(A); #P<0.05 vs cells in the presence of oxLDL (B). Figure shows one representative experiment. 
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DISCUSSION 
Hypoxia, HIF-1 and macrophages in human atherosclerotic plaques are correlated with intraplaque 
angiogenesis (Sluimer et al., 2008; Herrmann et al., 2006; Vink et al., 2007). Furthermore hypoxia 
stabilizes HIFs and leads to the accumulation of ado (Semenza 2001; Paul et al., 2004; Sluimer et al 
2008; Jiang et al., 2007; Wang et al., 1996; Conway 2003/2004; Kim et al., 2006; Loboda et al., 
2006; Jacobson et al., 2006; Yu et al., 2003; Gessi et al., 2004,2007; Kruth et al., 2002; Higuchi et 
al., 1993; Merighi et al., 2005; Kalayoglu et al., 1998; Baraldi et al., 2007; Herrmann et al., 2006; 
Vink et al., 2007; Blay et al., 1997). This study reports, for the first time, that ado increases HIF-1α 
protein levels in U937, HM and FC in hypoxia as already observed in cancer cells (Merighi et al., 
2005, 2006, 2007). A2B and A3 subtypes play a major role in the VEGF increase and FC formation 
and only the A2B is responsible for IL-8 stimulation induced by adenosine.  The normoxic 
modulation of HIF-1α by ado was only barely appreciated by means of western blotting experiments. 
However, by evaluating the HIF-1 DNA binding activity through an ELISA assay, ado was able to 
induce a significant increase of this response in hypoxia and a lower but significant effect in 
normoxia, according to the elegant study by De Ponti et al. (De Ponti et al., 2007). This result also 
suggests that, in the case of low signals, ELISA approach on nuclear extract is more sensitive than 
western blot on whole cell extracts. The possibility that the nucleoside could increase HIF-1α gene 
expression in normoxia was rejected due to the lack of mRNA modulation induced by ado, whilst 
addition of the protein translation inhibitor CHX revealed an effect on protein stability that was not 
detectable under hypoxic conditions. Furthermore, addition of rapamycin, reduced the nucleoside 
effect on HIF-1 DNA binding activity in normoxia, suggesting that adenosine may play a role also in 
protein translation (De Ponti et al., 2007). In hypoxia, our results with inhibitors of transcription and 
translation suggest that ado stimulates HIF-1α protein levels essentially by increasing translation, as 
transcription and stability did not appear to be altered by the nucleoside, according to what reported 
in cancer cells (Merighi et al., 2005, 2006, 2007). The role of ARs in the nucleoside regulation of 
HIF-1α was investigated by using ARs blockers. DPCPX, SCH 58261, MRE 2029F20 and MRE 
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3008F20, used at 100 nmol/L, a dose that may be considered selective for A1, A2A, A2B and A3 ARs, 
(Baraldi et al., 2008)  respectively, were able to reduce HIF-1α protein accumulation induced by ado. 
The involvement of all ARs was also confirmed by the increase of HIF-1α protein levels induced by 
high affinity AR agonists like CHA, CGS 21680, Compound 24 and Cl-IB-MECA for A1, A2A, A2B 
and A3 ARs, respectively. Furthermore, we found that silencing of A1 or A2A or A2B or A3 ARs was 
able to reduce HIF-1α modulation induced by ado and that the simultaneous knocking down of all 
four ARs abrogated the ado effect. Addition of oxLDL did not modify the responses of FC versus 
macrophages and U937 cells but we concentrated on FC because the effects of ado modulation of 
HIF-1α in this cellular type, crucial in atherosclerosis, have not been addressed before. However ox-
LDL are recognized by different receptors than minimally-oxidized LDL (mm-LDL) and it is likely 
that alternative LDL ligands such as mm-LDL might have different effects, with greater relevance to 
atherosclerosis (Boullier et al., 2006). Different receptor subtypes have been reported to play a role 
in the ado-induced HIF-1α accumulation depending on the cellular model investigated (Merighi et 
al., 2005, 2006, 2007; De Ponti et al., 2007; Ramanathan et al., 2007; Alchera et al., 2008; Wendler 
et al., 2007). The results of this study suggest that HIF-1α accumulation may be triggered by all ARs 
in FC analogously to their effect in activating other intracellular signalling factors like ERK1/2 
(Schulte et al., 2000). For example the ado-induced activation of myocardial ERK1/2 by statins has 
been found to involve A1, A2A and A2B ARs in mice (Merla et al., 2007). It is well known that HIF-1 
expression and activity, in addition to O2 concentration, are also regulated by important signal 
transduction pathways including those involving ERK/MAPK and Akt (Semenza 2002). As these 
pathways are also modulated by ado, our aim was to investigate the intracellular signalling triggered 
by this nucleoside in HIF-1α  modulation. Our results show the involvement of ERK1/2, p38 MAPK 
and Akt phosphorylation, whilst the Cl-IB-MECA effect was abrogated only by U0126. Indeed A1, 
A2A and A2B receptors activate ERK1/2, p38 MAPK and Akt, whilst the A3 subtype was involved in 
the modulation of ERK1/2. Several studies demonstrated a link between ado and HIF-1 at first in 
human cancer cell lines and then also in murine macrophages and in liver cells (Merighi et al., 2005, 
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2006, 2007; Ramanathan et al., 2007; Alchera et al., 2008). In most of these cases its accumulation 
was related to an increase of VEGF, which regulates important functions associated with 
angiogenesis. According to these results we found that ado increased VEGF levels through A3 and 
A2B receptors and to a lesser extent by the A2A subtype and was dependent by HIF-1α, pERK1/2, 
pp38 MAPK and pAkt. Recently, it has been reported that HIF-1 is also linked to IL-8 expression in 
human endothelial cells, (Kim et al., 2006) whilst other authors point to different mechanisms of IL-
8 regulation (Loboda et al., 2006) IL-8 is another crucial angiogenic factor found to be expressed by 
FC in human atheroma (Murdoch et al., 2005; Wang et al., 1996) and is also modulated by ado in 
different cellular models by activation of A2BARs (Feokistov et al., 2003). In this study we found 
that ado increased IL-8 secretion in hypoxic FC through activation of the only A2B subtype. 
However, in agreement with other authors, its modulation was not dependent by HIF-1α 
accumulation suggesting that other transcription factors, possibly AP-1, may be involved (Loboda et 
al., 2006). Finally, as HIF-1 has been demonstrated to promote FC formation (Jiang et al., 2007), we 
evaluated the involvement of ado in FC development. Our results clearly demonstrate that ado 
increases FC formation and that this effect is strongly reduced by A3 and A2B antagonists and by 
silencing HIF-1α; this suggests that under hypoxic conditions, ado by increasing HIF-1α, through 
activation of A3 and A2B ARs, promotes FC formation. The marginal role of the A2A antagonist in the 
modulation of this effect may be in line with recent relevant studies carried out by Reiss and 
Cronstein. These authors demonstrated that A2A agonists in normoxic conditions inhibited foam cells 
formation in stimulated THP-1 macrophages by increasing expression of cholesterol 27-hydroxylase 
and adenosine 5’-triphosphate-binding cassette transporter A1, that are proteins involved in reverse 
cholesterol transport (Reiss et al., 2004). The same authors demonstrated that A2A receptors were 
responsible for the atheroprotective effects induced by methotrexate (Reiss et al., 2008). Therefore it 
seems that adenosine by regulating FC may play both anti or pro-atherogenic effects depending on 
the receptors activated and the oxygen conditions present. 
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Altogether, these data suggest that in hypoxic conditions ado, through A3 and A2B ARs activation, 
induces HIF-1α protein accumulation thus leading to an increase of VEGF secretion and of FC 
formation; in addition the A2B subtype is responsible for IL-8 accumulation. Therefore AR 
antagonists and in particular A3 and A2B or mixed A3/A2B blockers may be useful in order to block 
important steps in the atherosclerotic plaque development mediated by ado. 
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